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Socio-economic Considerations under the 
Cartagena Protocol on Biosafety: Insights 
for Effective Implementation
Abstract: The inclusion of the socio-economic aspects in environmental 
decision-making has been practiced since the early seventies. The 
interactions between the environment and society, the growing demand 
for social responsibility and the pledge towards sustainable development 
are some of its drivers. However, in multilateral environmental agreements, 
particularly in the Cartagena Protocol on Biosafety (CPB), the integration 
of socio-economic matters in decision-making has been difficult and 
contentions. Article 26 of the CPB relates to socio-economic considerations 
arising from the impact of living modified organisms (LMOs) on the 
conservation and sustainable use of biological diversity. Contrary to the 
opinion of some scholars and the biotechnology industry, this article argues 
that Article 26 of the CPB: (a) recognises the sovereign rights of States in 
taking into account socio-economic considerations when making a decision 
of import of LMOs; (b) it has a wide scope since it deals with broad issues, 
namely conservation and sustainable use of biodiversity; and (c) is a cross-
cutting article within the CPB since, when included in decision-making, it 
relates to several operational provisions. Accordingly, the implementation 
of the CPB would be incomplete and not consistent with its objectives if 
socio-economic considerations are not appropriately and timely addressed 
in biosafety decision-making processes.
Key words: Living modified organisms, socio-economic considerations, 
Cartagena Protocol on Biosafety, decision-making.
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Briefing on the Current Status of Socio-economic Considerations 
under the Cartagena Protocol on Biosafety
The interconnections among ecological, social and economic aspects of any 
intervention (e.g. projects and technologies) have already received broad 
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acknowledgement in the international environmental community, and thus 
have a substantial trajectory on environmental decision-making. Practical 
applications of the eco-social interrelation started in the early 1970s 
when legislations begun to incorporate social impact assessments in their 
environmental procedures (Freudenburg 1986). Since then, the inclusion of 
socio-economic considerations in environmental decision-making processes 
has increased as a result of: (i) the evident mutual influence between the 
environment and society; (ii) growing demand for social responsibility by 
markets and regulations; and (iii) the imperative in advancing agendas 
towards sustainable development (Barrow 2002). 
Despite this progress – especially on the integration of the environmental 
and socio-economic fields at regulatory and research levels for assessing the 
drivers, impacts and outcomes of technology use – the incorporation of 
socio-economic considerations in multilateral environmental agreements 
(MEA) has been rather contentious. This is particularly true for the issue 
of the safety assessment of genetically modified organisms (GMOs) under 
the Cartagena Protocol on Biosafety (CPB), due to the politically charged 
and large economic incentives at stake.
The CPB is a MEA that aims at contributing to the safe transfer, handling 
and use of GMOs (referred in the Protocol as living modified organisms or 
LMOs) resulting from modern biotechnology. The focus of the Protocol is 
to prevent “adverse effects on the conservation and sustainable use of biological 
diversity, taking also into account risks to human health” (Article 1) (Secretariat 
of the CBD 2000:3). 
The negotiations of the text of the CPB took from 1995 to 2000 (year 
of its adoption). During this time, the inclusion of socio-economic aspects 
related to LMOs was one of the most difficult and contentions discussions, 
due to two opposing positions. On one hand, developing countries had 
wanted to include socio-economic considerations in risk assessment, risk 
management and decision-making procedures on LMOs. Several arguments 
on anticipated changes and potential threats were presented in this 
respect, particularly with regard to centers of origin and genetic diversity 
(e.g. impacts on biological diversity that may jeopardise rural livelihoods, 
indigenous knowledge, market opportunities end even national economies, 
among others) (MacKenzie et al. 2003; Khwaja 2002). On the other hand, 
most developed countries argued that socio-economic considerations were 
subjects “of little relevance and believed that further studies on the matter 
were not necessary” (Secretariat of the CBD 2003:79). Accordingly, they 
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sustained that social and economic issues were of reduced relevance in 
the context of the CPB since, in their view, they mostly relate to national 
interests (MacKenzie et al. 2003). The result of this long-standing debate is 
a broad compromise text on socio-economic considerations in Article 26 
of the CPB. After the Protocol’s entry into force, the process of decision-
making involving concrete measures for implementation of this article has 
also been characterised by intense discussions and contentious positions 
among Parties. The outcome to date has thus been a slow process to achieve 
further clarity and agreed guidance on how to address socio-economic 
considerations in the context of the CPB.
One standing topic under discussion has been the actual scope and 
extent of application of socio-economic considerations under the Protocol. 
Some countries (e.g. Argentina and the United States, both non-Parties to the 
CPB), some scholars and also the biotechnology industry argue that social 
and economic aspects should be of narrow scope and voluntary, so that their 
inclusion in biosafety decision-making do not delay the process of adoption 
of new technologies or increase the cost of compliance with the Protocol 
(Falk-Zepeda and Zambrano 2011; Falk-Zepeda 2009, see also the Global 
Industry Coalition submission in Secretariat of the CBD 2011a). Conversely, 
other countries (e.g. several from the African Group, Bolivia and Norway), 
scholars and some international NGOs sustain that Article 26 spells out the 
right of countries to include socio-economic considerations in the biosafety 
decision-making process. This position is based on the argument that 
development and adoption of technologies have a wide array of ecological 
and socio-economic implications. Moreover, these biosafety actors sustain 
the importance of effectively addressing the social and economic dimensions 
of LMO introduction in light of sustainable development (Secretariat of the 
CBD 2011a; Pavone 2011; MacKenzie et al. 2003). 
In spite of the unresolved issues and the lack of guidelines for effective 
implementation of Article 26, socio-economic considerations are integrated 
in biosafety decision-making and regulatory frameworks in a number of 
countries. For instance, by 2010, according to Spök (2010), the following 
sixteen Parties to the CPB incorporate provisions on socio-economic impacts 
in their national biosafety regulations: Armenia, Austria, Bangladesh, 
Bhutan, Cambodia, China, France, Honduras, India, Lebanon, Mauritius, 
Nigeria, Norway, the Philippines, South Korea and Syria.   
Contrary to some opinions for restricted application and marginal 
relevance, the actual language of Article 26 is rather wide in scope and 
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cross-cutting in nature. This because it deals with the core issues between 
the CPB and its mother treaty (the Convention on Biological Diversity, 
CBD): Conservation and sustainable use of biological diversity. Hence, 
when implemented, Article 26 inherently relates to several other provisions 
of the Protocol. 
The interconnection of Article 26 with several other articles of the 
CPB is pointed out in the Explanatory Guide to the Cartagena Protocol 
on Biosafety. This Guide is an internationally recognised document that 
provides orientation for the interpretation of the CPB, which was prepared 
by scholars in law and reviewed in a series of workshops by different 
biosafety stakeholders (including governmental delegates and members of 
the Intergovernmental Committee for the Cartagena Protocol) (MacKenzie 
et al. 2003). Nonetheless, the relationship of Article 26 with other 
stipulations of the CPB has not yet been further analysed. The purpose of 
this article is to provide insights on the wide scope of the Article 26 on socio-
economic considerations (specifically on Article 26.1) and its connection 
to other operational articles of the Protocol. 
Article 26 of the Cartagena Protocol on Socio-economic Considerations
Article 26 of the CPB contains two provisions, from which Article 26.1 is 
operational in relation to biosafety decision-making. Article 26.1 states: 
“The Parties, in reaching a decision on import under this Protocol or under its 
domestic measures implementing the Protocol, may take into account, consistent 
with their international obligations, socio-economic considerations arising from 
the impact of living modified organisms on the conservation and sustainable use 
of biological diversity, especially with regard to the value of biological diversity to 
indigenous and local communities.” (Secretariat of the CBD 2000:19). 
The text of Article 26.1 contains a number of relevant elements for 
analysis. For this article, however, we will focus on only a few: (i) the 
meaning of the text “may take into account” as recognition of the sovereign 
right of Parties; (ii) the broad scope set by the wording “conservation and 
sustainable use of biological diversity”; and (iii) the cross-cutting nature of 
Article 26.1 set by the text: “The Parties, in reaching a decision on import 
under this Protocol”.
“…may take into account” as a Recognition of Sovereign Rights
The wording “may take into account” in Article 26.1 has been interpreted 
by some as a text that points to a voluntary measure, over stressing 
that Article 26.1 is not an obligatory CPB provision (GIC 2012; 
5Falk-Zepeda and Zambrano 2011; Falk-Zepeda 2009). This interpretation 
has important shortcomings. First, it ignores the context from which the 
language of Article 26.1 results. In international negotiations, a common 
practice is the inclusion of compromise texts on contentious matters in 
order to reflect the various concerns of the different positions. Article 26.1 
is a compromise text that, to some extent, addresses the positions of both 
developing and developed countries during the discussions on the inclusion 
of socio-economic aspects in the LMOs biosafety process (Khwaja 2002). 
Second, it erroneously suggests, in a subtle manner, that Article 26.1 would 
be a provision low in hierarchy of implementation. 
Conversely, a more comprehensive analysis is that Article 26.1 
establishes the right of Parties to the CPB to take into account socio-
economic issues in the decision-making process related to LMOs. As stated 
by Khwaja (2002:361) – a negotiator of the text of the CPB – “Article 26 is to 
empower Parties of import to analyse carefully what possible adverse impacts the 
import of LMOs would have on their socio-economic conditions”. Accordingly, its 
incorporation in biosafety decision-making does not breach the Protocol. 
This understanding seems consistent with Article 2.4 of the CPB on General 
Provisions. Article 2.4 acknowledges that the Protocol does not restrict to 
Parties in taking any measure that may contribute to better protection of 
the conservation and use of the biological diversity. The literal wording 
of Article 2.4 is: “Nothing in this Protocol shall be interpreted as restricting the 
right of a Party to take action that is more protective of the conservation and 
sustainable use of biological diversity than that called for in this Protocol, provided 
that such action is consistent with the objective and the provisions of this Protocol 
and is in accordance with that Party’s other obligations under international law.” 
(Secretariat of the CBD 2000:3). 
Accordingly, Article 26.1 of the Protocol goes beyond merely stating a 
voluntary measure but establishes and confirms the right, in international 
law, of the Parties to take account of socio-economic considerations in 
biosafety decision-making processes. Whether or not Parties choose to 
exercise this right is up to them in accordance to their specific social and 
economic priorities and interests. However, the right is clearly defined, 
and its recognition as such is particularly relevant for: (a) countries that 
are centers of origin and genetic diversity, due to the close interconnection 
between biodiversity and local communities (Serratos 2009; IAASTD ed. 
2009); (b) countries that have large indigenous or rural populations given 
their relationship with and dependence on biodiversity (Maffi and Woodley 
2010; CEC 2004); and (c) countries that have an important portion of their 
Socio-economic Considerations under the Cartagena Protocol on Biosafety
6     Asian Biotechnology and Development Review
economy and development programmes reliant on the use of biodiversity 
(e.g. sustainable management of agrobiodiversity as part of local agricultural 
and development agendas) (IAASTD ed. 2009; Nuffield Council of 
Ethics 2004).
Biodiversity Conservation and Sustainable Use: Broad in Themselves
In the CPB discussions on socio-economic considerations, the position of 
some countries, observers and stakeholders is that the implementation 
scope of Article 26.1 is narrow and strictly limited to biodiversity issues 
(GIC 2012; Secretariat of the CDB 2011a; Falk-Zepeda and Zambrano 
2011; Falk-Zepeda 2009). Based on the text of Article 26.1, socio-economic 
considerations as stated in the Protocol are certainly related to the effects 
on biological diversity specifically to its conservation and sustainable 
use, and particularly to the value of biodiversity to indigenous and local 
communities. Yet, these specifications are far from being narrow when 
analysed from a technical and, consequently, decision-making point of view. 
The specifications in Article 26.1 in relation to biodiversity set its wide 
scope of application based on the following:
•	 Biodiversity is a broad concept in itself that embraces all forms of life and 
their environments (including their living and non-living components). 
This is described in the CBD´s definition on biological diversity and 
ecosystems as follows: “Biodiversity” refers to “the variability among living 
organisms from all sources including, inter alia, terrestrial, marine and other 
aquatic ecosystems and the ecological complexes of which they are part: this 
includes diversity within species, between species and of ecosystems”; while 
“ecosystem” is described as: “dynamic complex of plant, animal and micro-
organism communities and their non-living environment interacting as a 
functional unit” (Secretariat of the CBD 1992:3).
•	 Impacts on biodiversity relate to a large spectrum of possible effects. 
There is widespread and well-documented recognition that any 
impact on biodiversity or ecosystems does not take place in a linear 
or necessarily scale-dependent manner. On the contrary, changes 
in biodiversity are complex and unpredictable, which may result in 
cumulative and combinatorial effects that can accelerate changes or lead 
to unintended adverse effects (Cardinale et al. 2012). In simpler words, 
any change on biodiversity can result in a chain of other alterations and 
consequences either direct, indirect, intentional, accidental, predicted 
and/or unforeseen (Stabinsky 2001). The wording in Article 26.1 
7“socio-economic considerations arising from the impacts of living modified 
organisms on the conservations and sustainable use of biological diversity” 
refers to all these different kinds of possible effects. 
•	 Conservation and particularly sustainable use of biodiversity have 
an intrinsic socio-economic component. On one hand, the “use” 
of biodiversity is defined by social, cultural and economic factors. 
Moreover, the biological and socio-cultural components of life that 
define the consuetudinary practice (such us use of local biodiversity 
for food or income generation) are inseparable, particularly among 
indigenous communities (Prilgrim and Pretty 2010; Maffi 2010; 
Cardinale et al. 2012). On the other hand, the use of biological diversity 
in a “sustainable manner”, as pledged by the CBD and CPB, entails the 
management of biodiversity by individuals and groups. Accordingly, 
the societies and socio-economic factors in which these individuals and 
groups are embedded play a crucial role in the long-term preservation 
of biodiversity while securing the fulfilment of the needs of the present 
and future generations (Borrini-Feyerabend et al. 2004).
In summary, the specification of socio-economic considerations “arising 
from the impacts of LMOs in relation to the conservation and sustainable use 
of biodiversity” is broad in its very essence. It includes the direct, indirect, 
intentional, accidental, predicted and unforeseen effects on the different 
forms of life and their environments, and on their potential use in light of 
the sustainability principles.  Furthermore, the text “especially with regard to 
the value of biological diversity to indigenous and local communities” of Article 
26.1 keeps its scope appropriately wide by pointing out that besides the 
broad array of implications on biodiversity and sustainable use in general, 
additional (and not restricted to) considerations are needed relative to 
the livelihood, consuetudinary use, culture, spirituality and others where 
biodiversity plays an important role for indigenous and local communities. 
The Cross-Cutting Nature of Article 26 on Socio-economic Considerations
Other proposed interpretations of Article 26 in general, and Article 
26.1 in particular, are: (a) It deals with a very specific issue within the 
Protocol; and (b) If it is to be included in biosafety decision-making, it 
should be treated in a separate manner in relation to the other provisions, 
particularly to the risk assessment (Falk-Zepeda and Zambrano 2011). 
These interpretations mistakenly place Article 26 as an isolated or virtual 
stand-alone clause. Nonetheless, the text “The Parties, in reaching a decision 
on import under this Protocol” opens up for the inclusion of Article 26 with 
Socio-economic Considerations under the Cartagena Protocol on Biosafety
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respect to other Protocol’s provisions when, upon the discretion of Parties, 
a comprehensive analysis is applied (MacKenzie et al. 2003). In this regard, 
the next paragraphs describe the possible – and non-exhaustive – range 
of the implications and integration of Article 26 along the whole body of 
the Protocol.
To begin with, Article 26.1 clearly states that “in reaching a decision on 
import” under the Protocol, Parties may take into account socio-economic 
considerations. This wording has two important implications. First, it 
indicates “when” socio-economic aspects can be considered: This is at the 
time of reaching a decision on import. Second, it leads to two key articles 
related to the general modus operandi for taking a decision on import of 
LMOs: (a) Article 10 on Decision Procedure; and (b) Article 11 on Procedure 
for Living Modified Organisms Intended for Direct Use as Food or Feed, or 
for Processing. These articles are central in guiding the steps for decision-
making under the Protocol and are linked to other important operative 
provisions (Figure 1, Figure 2 and Figure 3). In light of this, the relationships 
of Article 26.1 with other Protocol articles would be as follows:
•	 In relation to Article 10 (see the process A, Figure 1), on one hand, it 
would arguably relate socio-economic considerations to Article 15 on 
Risk Assessment and Annex III of the CPB, for taking into account social 
and economic issues in parallel to the environmental risk assessment. 
Although Annex III mostly refers to highly technical environmental 
aspects, the implementation of Article 15 shall also take into account 
human health (in consistency with the Protocol’s objective). This 
defines the possibility of including in the risk assessment relevant 
public health issues – a highly relevant socio-economic subject – in 
relation to adverse effects of LMOs on the conservation and sustainable 
use of biological diversity. Furthermore, Article 10.3(c) opens up 
the possibility for including socio-economic considerations in risk 
assessment processes under the CPB by stating that Parties, in the course 
of taking a decision, can request “additional information in accordance 
with its domestic regulatory framework or Annex I” (Secretariat of the CBD 
2000:7). Accordingly, supplementary information could be, among 
other things, a socio-economic impact assessment. This approach will 
lead to a more systemic evaluation of risks and contribute to overcome, 
at least partly, the current limitations of assessments mostly focused 
on restricted environmental aspects (Meyer 2011). Additionally, Annex 
I under item (l) requests information on “Suggested methods for safe 
handling, storage, transport and use, including packaging, labeling, […]” 
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(Secretariat of the CBD 2000:27). This provision relates to socio-
economic matters as well, which are important to identify. For instance, 
conditions for segregation during storage and transport, or intended and 
other potential local uses of the LMO in question, are socio-economic 
considerations that will impact the safe handling, storage, transport 
and use of LMOs. 
Upstream in the process of decision-making, Article 10, and subsequently 
Article 26.1, relates to: 
  Article 7 on the Application of the Advance Informed Agreement 
Procedure (AIA): and
  Article 8 on Notification, which also refers to Annex I, where – 
as indicated previously – socio-economic information could be 
requested by the notified Party. 
Downstream, Article 10, and then Article 26.1, is linked to: 
  Article 16 on Risk Management under which measures to prevent 
or regulate, manage and control socio-economic risks could be 
identified. 
  Article 21 on Confidential Business Information that mentions, 
among others, that information relevant to the risk assessment and 
the one generated according to Annex I of the CPB cannot qualify as 
confidential. In relation to risk assessment, “relevant information” 
could entail information with socio-economic connotations (e.g. in 
relation to the Protocol’s objectives, findings on impacts on human 
health from the public health point of view).
  Article 12 on Review of Decisions, which indicates that decisions 
on LMOs could be reviewed in light of new scientific information 
on potential adverse effects on the conservation and sustainable 
use of biological diversity, taking into account human health. New 
scientific information could refer to impacts of LMOs that may have 
socio-economic implications, including potential changes in human 
health from the public health perspective.
•	 In relation to Article 11 (see the process B, Figure 2), is the other 
provision that would relate to Article 26.1 in the process of taking a 
decision on import of a LMO, in this case when the LMO is intended 
for direct use as food or feed, or processing (LMO-FFP). Accordingly, 
it could be interpreted as allowing the inclusion of socio-economic 
considerations through: 
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  Annex II specifically under item (k) that requests suggested methods 
for safe handling, storage, transport and use of LMO-FFPs, since 
these processes involve socio-economic aspects as described before;
  Article 15 and Annex III according to Article 11.6(a) on the risk 
assessment as a source of information for the process of decision-
making; and 
  Article 16 on Risk Management and Article 12 on Review of 
Decisions, in line with what was mentioned previously.
Furthermore, an overarching feature of Article 11 is that it is subject 
of socio-economic considerations. This is because its implementation 
is triggered when a Party has adopted a decision “regarding domestic use, 
including placing on the market” of a LMO-FFP (Article 11.1). “Domestic use” 
and “placing on the market” are inherently socio-economic processes. Hence, 
reaching a decision on these matters necessarily social and economic factors 
need to be taken into account.
Besides Article 10 and Article 11 on the decision procedures on import 
of LMOs, the implementation of Article 26.1 could also relate to Article 17 
and Article 25 as follows (see the process C, Figure 3):
•	 In relation to Article 17 on Unintentional Transboundary Movements 
and Emergency Measures, socio-economic issues can be considered for 
determining the impacts that may arise from such movements and 
the corresponding response measures. On one side, Articles 17.3(c) 
and 17.3(d) request available information on possible adverse effects 
and other relevant information, respectively, in notifications to States 
affected or potentially affected by unintentional transboundary 
movements of LMOs. Such information could include socio-
economic considerations. On the other side, under Article 17.4 social 
and economic issues could be taken into account to determine the 
appropriate responses, necessary actions or emergency measures. 
Moreover, those response and emergency measures could address the 
socio-economic impacts arising from adverse effects on the conservation 
and sustainable use of biodiversity, taking into account human 
health, and related to unintentional transboundary movement of an 
LMO. Finally, Article 17 also relates to Article16 on risk management 
giving place, as indicated earlier, to the identification of actions to 
prevent, regulate, manage and control potential risks, which could 
arguably include socio-economic impacts. Specifically, Parties may 
incorporate socio-economic considerations in their responses to prevent 
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unintentional transboundary movements under Article 16.3, and could 
take appropriate risk management measures to prevent any adverse 
effect, including socio-economic effects, according to Article 16.2. 
•	 As for Article 25 on Illegal Transboundary Movements, socio-economic 
considerations may contribute to the identification of any potential 
adverse effects and the related response measures.
Finally, Article 26 is linked the following overarching CPB articles: 
•	 Article 20 on Information Sharing and the Biosafety Clearing House 
that mandates making available relevant information on biosafety, 
for instance regulations, decisions and assessments on or related to 
socio-economic considerations of LMOs. This activity on information 
sharing on is also directly connected to Article 26.2 on “cooperation on 
research and information on any socio-economic impacts of living modified 
organisms, especially on indigenous and local communities” (Secretariat of 
the CBD 2000:19).
•	 Article 22 on Capacity Building for cooperating in the development 
and strengthening human resources and institutional capacities 
for including, among others, socio-economic considerations in the 
decision-making process and effective implementation of the Protocol. 
The capacity building scope of Article 21 is directly related to Article 
26.2 as well.
•	 Article 23 on Public Awareness, Education and Participation to 
which Article 26 is linked for: (a) The promotion and facilitation of 
public awareness and education on socio-economic considerations; 
(b) Participation of the public in the identification of socio-economic 
impacts; and (c) Valuation of socio-economic impacts in the decision-
making processes. 
•	 Nagoya – Kuala Lumpur Supplementary Protocol on Liability and 
Redress to the Cartagena Protocol on Biosafety, particularly in relation to 
Article 12 on Civil Liability. Article 12.2 of the Supplementary Protocol 
mentions the alternatives that Parties could adopt in order to provide 
“adequate rules and procedures in their domestic law on civil liability for 
material or personal damage” (Secretariat of the CBD 2011b:7) on the 
conservation and sustainable use of biological diversity taking into 
account human health. Potential material damage may refer to any 
economic adverse effects that could result from changes in the biological 
diversity. Whereas personal damage could mean negative impacts on 
human health in the context of the CPB.
15
Based on this analysis, Article 26 has multiple interconnections with a wide 
range of provisions of the Protocol. Accordingly, it cannot be assumed as 
an isolated article.
Conclusion
Article 26 of the Protocol is the recognition of the sovereign right of Parties 
to include, as necessary, socio-economic considerations for conserving and 
using sustainably biological diversity. Because biodiversity conservation 
and sustainable use (the core aims of the Protocol as well as of Article 26) 
are broad concepts involving all forms of life, their environments and their 
management, Article 26 is also inherently broad in scope. Additionally, 
the inclusion of socio-economic considerations arising from LMOs when 
reaching a decision of import of such organisms is not a marginal matter 
within the Protocol. This is because, Article 26 contributes to the objective 
of the Protocol: “[E]nsuring an adequate level of protection in the field of safe 
transfer, handling and use of [LMOs] […] that may have adverse effects on the 
conservation and sustainable use of biological diversity taking into account 
human health” (Secretariat of the CBD 2000:3). In line of this, it is important 
to highlight that: (i) Consideration of human health in the context of 
biological conservation and sustainable use, as well as safe transfer, handling 
and use of LMOs are intrinsically social and economic processes; and 
(ii) Most national country decisions (e.g. such as import of LMOs) are taken 
upon socio-economic arguments (Khwaja 2002). 
Certainly, along the implementation of the Protocol, socio-economic 
considerations cannot have a higher relevance than ecological issues, 
particularly more than conservation of biological diversity. However, their 
relevance cannot be neglected either since they are crucial for achieving 
sustainable management (or sustainable use, in the terms of the CPB). For 
this, the implementation of the Protocol would be incomplete, and not 
consistent with its objectives, if not adequately addressing socio-economic 
considerations when reaching a decision on import of a LMO.
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Introduction
Provision in the Cartagena Protocol
The Cartagena Protocol on Biosafety under Article 26 establishes the right 
of Parties to take into account socio-economic considerations arising from 
the impact of living modified organisms (LMOs) on the conservation 
and sustainable use of biodiversity in reaching a decision on whether to 
import LMOs especially with regard to the value of biological diversity 
to indigenous and local communities. This must be done in a manner 
consistent with the existing international obligations by which countries 
may be bound. While the Article provides a fairly limited set of conditions 
under which socio-economic considerations may be taken into account in 
20     Asian Biotechnology and Development Review
decision-making regarding imports, countries may also incorporate socio-
economic considerations other than those explicitly included in Article 26 
into their domestic regulatory regimes on biosafety, as long as they comply 
with other international obligations. Under paragraph 1 of the Article, 
the Protocol appears to limit the scope of socio-economic considerations 
that governments may take into account in regulatory decisions to such 
circumstances as the impact of the import of LMOs on: (i) the continued 
existence and range of diversity of the biological resources in the areas 
inhabited or used by indigenous or local communities;(ii) the loss of 
access to genetic and other natural resources, as a result of biodiversity 
loss, previously available to indigenous or local communities in their 
territories; and (iii) the loss of cultural traditions, knowledge and practices 
in a particular indigenous or local community as a result of the loss of 
biological diversity in the community’s territory. (MacKenzie et al. 2003)
Paragraph 2 of the same Article, however, encourages Parties to the 
Protocol to cooperate on research and information exchange on any socio-
economic impacts of LMOs, especially – but not limited to – impacts on 
indigenous and local communities. Socio-economic considerations are 
relevant to domestic biosafety decisions and not just to transboundary 
movement of LMOs. In this regard, countries may incorporate into their 
domestic regulatory regimes on biosafety socio-economic considerations 
other than those explicitly included in Article 26, as long as these rules 
comply with any other international obligations by which they may be 
bound (Garforth 2004). At the same time, keeping to the spirit and letter of 
the Protocol, it could be prudent if Parties are to avoid disputes with their 
trading partners, such as complaints under the World Trade Organization 
(WTO). The WTO rules tend to emphasise decision-making procedures that 
rely on rules and regulations that center around scientific risk assessments, 
while limiting decision-making based on non-safety issues. The strict 
emphasis on scientific risk assessments under the WTO, are sometimes 
relaxed within implementation agreements, such as the Sanitary and 
Phytosanitary Measures agreement (Zepeda 2009).
Malaysia’s  Experiences
National Biological Resources
According to the 2001 Global Diversity Outlook, Malaysia is one of 12 
megabiodiverse countries of the world. Although Malaysia has only 0.2 per 
cent of the world’s land mass, the diversity of its flora and fauna makes it one 
21
of the richest countries in terms of biodiversity per unit area, as measured 
by the World Development Indicators. Notwithstanding that there is no 
definite data on the exact number of species in Malaysia, especially for 
small organisms such as insects and worms, a conservative estimate is that 
Malaysia has at least 170,000 species. With such rich biodiversity housed in 
a diverse habitats such as seas, rivers, swamps, mountains and forests, it is 
imperative that biotechnology products advance safely from the laboratory 
to field tests and are released to the environment without adverse impact 
on its biodiversity and the environment. 
The National Policy on Biological Diversity, launched in April 1998, 
calls for the sustainable utilisation of our biological resources among 
others through biotechnology and the need to establish a legal framework 
on biosafety.  For this reason, Malaysia signed the Cartagena Protocol on 
Biosafety on May 24, 2000 and subsequently ratified it on September 3, 2003.
National Policy on Biotechnology
The biotechnology sector including modern biotechnology has been 
identified as a new engine of growth for Malaysia as reflected in the National 
Biotechnology Policy 2005 (NBP) and the 9th (2006-2010) and 10th (2011-
2015) Malaysian Plans. Under NBP legislative and regulatory framework 
development component, it aims to create an enabling environment 
through continuous review of the country’s regulatory framework and 
procedures in line with global standards and best practices as well as 
developing a strong intellectual property regime to support research and 
development and commercialisation efforts. 
Prior to the launching of the biotechnology policy there were very few 
research and development activities in modern biotechnology. In fact, it 
was mostly on the import of genetically modified (GM) grains for food, feed 
and processing. Since 1998, that is prior to the existence of biosafety law, 
all such applications were processed by an informal Genetic Modification 
Advisory Committee. 
Experience in Forming a National Legal Framework on Biosafety
It was a landmark achievement for Malaysia when the Biosafety Act was 
passed by the Malaysian Parliament on July 11, 2007.  The passing of the 
Act can be seen as a positive and promising beginning for Malaysia to take 
proactive approaches towards protecting human health and the environment 
from the possible adverse effects of the products of modern biotechnology 
as well as fulfilling Malaysia’s obligation under the Cartagena Protocol. 
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Accordingly, the Act was enforced effective on December 1, 2009, two 
years after it was passed by the Parliament.  This was followed by development 
of appropriate forms for application for release and notification for research 
works.  As provided under the Act, and the understanding with stakeholders, 
the Biosafety (Approval and Notifications) Regulations 2010 was formulated 
and enforced effective November 1, 2010. The Act, Regulations, Application 
Forms and Institutional Biosafety Committee Guidelines form the key 
elements of the biosafety legal framework in Malaysia.  
Consistent with the above framework, the National Biosafety 
Board (NBB), responsible for making decision pertaining to the release, 
importation, exportation and contained use of any LMOs derived from 
modern biotechnology, was formed in March 2010. The Chairman of 
the NBB is the Secretary General of the Ministry of the Natural Resources 
and Environment and its members comprise representatives from six 
other relevant ministries and four other persons with knowledge and 
experience in disciplines or matters relevant to the Biosafety Act. The 
Genetic Modification Advisory Committee (GMAC), consisting of experts 
from various science-based and other relevant disciplines working with 
the Government agencies, research institutes, private sectors and Non-
Governmental Organisations to provide scientific, technical and other 
relevant advice to the NBB, was established in May 2010.
To operationalise the law and to support the NBB and GMAC, a 
dedicated department named the Department of Biosafety, was formed in 
May 2010, headed by Director General of Biosafety who is also the Secretary 
to the NBB. The Department also acts as a one stop centre for all activities 
relating to biosafety in Malaysia in addition to fulfilling its core functions, 
that is becoming secretariat to the NBB, GMAC and committees or sub-
committees established under the NBB and GMAC.
In 2010, Malaysia, for the first time, made decisions on LMOs based on 
a proper legal framework, processes and appropriate procedures in place. 
As of July 31, 2012, the NBB had made decisions on eight applications on 
approval for release and twelve notifications on activities in contained 
environment (including the approval by informal GMAC).
Provision on Socio-Economic Requirement in the National Legal Framework
Consistent with the Cartagena Protocol under Article 26 which states, socio-
economic considerations should be taken into account in implementing 
the national biosafety law, section 35 of the Malaysian Biosafety Act states: 
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“The Board or Minister shall not be prevented from taking a 
decision, as appropriate, under Part III or Part IV, where there is lack of 
scientific certainty due to insufficient relevant scientific information 
and knowledge regarding the extent of the potential adverse effects of 
living modified organisms or products of such organisms on human, 
plant and animal health, the environment and biological diversity and 
may also take into account socio-economic considerations.”
(Part III of the Biosafety Act refers to the approval process for release 
and import, Part IV to the notification process for export, contained use 
and import for contained use.)
It was not easy to get the industries to accept the provision on “may 
also take into account socio-economic considerations”. As more clarity 
was requested on these terms, the Biosafety (Approval and Notification) 
Regulations 2010 in section 25 on socio-economic considerations provides 
extended explanation as follows:  
“The Board or the Minister, in taking into account socio-economic 
considerations pursuant to section 35 of the Act, may consider:
a. the changes in the existing social and economic patterns and means 
of livelihood of the communities that are likely to be affected by the 
introduction of the living modified organisms or products of such 
organisms;
b. the effects of the religion, social, cultural and ethical values of 
communities arising from the use or release of the living modified 
organisms or products of such organisms”.
Considerations of Socio-economic Aspects in Decision Making
Socio-economic considerations are important and sometimes even crucial 
in safeguarding the interests of indigenous and local communities in 
technology adoption. However, without clear parameters for the scope of 
socio-economic considerations of LMOs within the Cartagena Protocol, 
Malaysian uses the provision under section 25 of the Biosafety (Approval 
and Notification) Regulations 2010. The legal experts had great difficulty 
to include section 25 of the Regulations due to the possibilities of many 
interpretations of such a provision. It was clear then that this provision 
will have to be supported by some practical guidelines.
Socio-economic considerations can be taken into account in at least 
four different phases in biosafety decision making: during the development 
of a domestic biosafety regulatory regime; during the risk assessment for a 
particular modified organism; after a risk assessment – for example, during 
risk management, when decisions must be made as to whether identified 
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risks are acceptable; and during the appeal, review or renewal of a permit 
(Garforth 2004). The need for assessing the potential socio-economic 
impacts of LMOs is hinged on several important reasons including social 
responsibility, inter-generational responsibility, and social acceptance 
and reducing the long-term cost (Yoke Ling 2008). The assessment 
meanwhile can focus on three main elements: firstly, economic impacts 
such as distribution of benefits, research and development efforts by public 
institutions, labour, organic market, intellectual property right and control 
over the tools of production; secondly, social and cultural issues which 
include public opinion and impact to small holders; and finally, ethical 
considerations.
However, to date there are not many countries that have carried out 
socio-economic analysis for the consideration in the decision making 
about LMOs. Furthermore, socio-economic considerations in this regard is 
an area gradually emerging and will take a long lead time before a proper 
framework for economic analysis could be established. Thus, for the time 
being, it is likely that socio-economic considerations as are applied in 
other areas may be adopted as appropriately.  In Malaysia, socio-economic 
considerations may become very important if the plantation industry of 
the primary commodities like oil palm, rubber, cocoa and others migrate 
into LMOs options of high productivity or high value added products at 
some stage. The small holders will then face problems of having to compete 
with plantations owners in selling their non-LMOs products. However, such 
problems may be resolved based on current experiences in related sectors.
In Malaysia, dealings with LMOs are mainly related to import of GM 
grains. So far the NBB has approved six types of grains. As these grains will 
not be able to grow in Malaysia, the possibilities of any socio-economic 
problems are quite remote. All approvals on such grain are imposed with 
appropriate terms and conditions including submitting regular reports of 
spillage and clear labelling of the product from importation down to all 
levels of marketing stating that it is only for the purpose of food, feed and 
processing and is not to be used as planting material. As corn is grown in 
some parts of Malaysia, growth of spilled GM grains during transportation 
may pose contamination though the probability is very low.  
So far Malaysia has not come across any socio-economic situations 
in the conservation and sustainable use of biodiversity as highlighted 
by MacKenzie et al. (2003) as the country is still in its infancy in 
the development of modern biotechnology. However, with the fast 
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developments in biotechnology in other parts of the world, LMOs will 
continue to come into the country and the biosafety regulatory body in 
Malaysia will have to be vigilant to minimise impact especially with regard 
to the value of biological diversity to indigenous and local communities. 
The consistently growing socio-economic problems arising from the 
increasing death cases caused by dengue fever from Yellow Fever Mosquito 
(Aedes aegypti) in Malaysia and in many parts of the world have facilitated 
the release of genetically modified mosquitoes and other genetically 
modified products like TMOF (Trypsin Modulating Oostatic Factor) to 
reduce the population of wild mosquitoes. In both cases, the release could 
also be supported by the fact that country may partly own the intellectual 
property right of the innovations.
In order to seek for more inputs on socio-economic consideration, 
it is important that a wider public consultation is carried out including 
through surveys. Though sometimes there may be multiple submissions 
on the same issue, particularly when some championing bodies are driving 
the submission, it would still be a worthwhile exercise to do as it may be 
able to identify a spectrum of issues and views.  For example, a survey 
carried out by the Department of Biosafety in 2011 with about 1500 target 
participants indicated that more than 50 per cent supported the release 
of GM mosquitoes. Though it was a small survey, the result was useful to 
reflect that people are not completely against GM mosquitoes. This can 
be easily rasionalised as those affected by death cases arising from Dengue 
would surely like to see the problems solved. 
It is understandable that due to the nature of the subject, to include 
socio-economic considerations in the decision making based on detailed 
analysis is indeed difficult, time consuming and an expensive job.  Parties 
have their sovereign right to decide what is appropriate to their society 
based on facts in hand. However, decision may be reviewed when new and 
credible information is made available.
Setting up Socio-economic Committee under the National Biosafety Board
Malaysia realises that in the future socio-economic issues may play 
an important role in the decision making on LMOs. As such it was 
recommended to the NBB that a Socio-Economic Committee is set up 
similar to the Genetic Modification Advisory Committee as the Biosafety 
Act provides for such an option. It is important that such a committee 
be established at the earliest possible time to enable members to build 
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their capacity in this area.  However, as socio-economic issues can be 
very sensitive at times, and based on experiences in other areas such as 
environment, the NBB decided to set up just an informal advisory group. 
The Board is now hunting for experts from institutions of higher learning 
who are experienced in socio-economic analysis and who can be groomed 
in socio-economic analysis as applied to LMOs. The group when established 
and fully operational is expected to advise the NBB on request and on a 
case by case basis.
A synergetic event to the above was the launching of the National 
Bioethics Council (NBC) of Malaysia under the Ministry of Science, 
Technology and Innovation in May 2012 with the aim to provide advice, 
resolve and manage bioethical issues in the country. It was also aimed 
at promoting ethics in science and technology so that the development 
would not give contradicting impact on human and moral values, 
especially concerning the environment, social, health, culture, laws and 
religions. The council’s main term of reference is mainstreaming bioethics 
and disseminating information on bioethical issues among people from 
all walks of life, including scientists. Although its general focus will be 
on technology applications and issues concerning stem cell, genetically-
modified organisms, animal testing and synthetic biology, attention 
would also be given to integrity issues and matters constituting a conflict 
of interest. The council comprises experts from various disciplines related 
to bioethics, scientist and non-scientist, policy makers and stakeholders 
entrusted to collectively study the issues and challenges faced by the 
country in promoting new technologies. The establishment of National 
Bioethics Council opens a window for consultation by NBB thus 
complementing its effort. As this is a new set up, the working mechanism 
between the NBC and the NBB will have to be periodically reviewed to 
ensure effectiveness.
Socio-economic Considerations for GM Mosquito and TMOF
The following two cases are examples whereby the National Biosafety Board 
made their decision by also considering socio-economic aspects:
i) Genetically Modified Mosquito (GM Mosquito)
The National Biosafety Board on the October 5, 2010 made a decision 
to grant approval with terms and conditions to the application from the 
Institute of Medical Research (IMR) for a field trial to release transgenic 
male mosquitoes. This approval permits the release of male GM Yellow 
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Fever mosquitoes, Aedes aegypti OX513A(My1) strain and male non-GM 
Aedes aegypti mosquitoes (wild type) to conduct a field trial entitled 
“Limited Mark-Release-Recapture (MRR)” of Aedes aegypti wild type and 
OX513A(My1). The proposed release sites were in Bentong, Pahang and 
Alor Gajah, Melaka. The recommendation of GMAC to the NBB was for 
an approval with terms and conditions. Proper risk management strategies 
were to be followed as stipulated through the terms and conditions 
imposed. Additionally close monitoring is to be done to ensure that the 
terms and conditions imposed are implemented on the ground. Public 
consultation for this application was done in August 2010 for a period 
of 30 days. Concerns raised by the public were addressed and taken into 
consideration when making the decision. The basis of NBB decision is as 
follows which also include socio-economic considerations:
•	 The proposed field experiment is only for a limited small scale release 
and does not endanger biological diversity or human, animal and 
plant health when proper risk management strategies are followed 
as stipulated through the terms and conditions imposed with the 
approval.
•	 Risks identified for this field experiment were quite low in the context 
of a limited Mark-Release-Recapture field experiment. However, for a 
larger scale release, these risks will be re-evaluated.
•	 Only a small number of mosquitoes will be released in comparison to the 
existing wild population based on previous baseline population surveys 
conducted by IMR. In addition, the released GM mosquitoes have no 
selective survival advantage and will diminish through the process of 
natural selection.
•	 The proposed release site will be free from any dengue outbreak for 
at least three months before the start of the field trial and this will be 
verified by the relevant health authorities.
•	 Only male mosquitoes are released and male mosquitoes do not bite or 
carry the dengue virus. The Standard Operating Procedures for sorting 
the male mosquitoes for the release has been assessed and approved by 
GMAC. Sorting will be done mechanically, followed by a serial manual 
re-check on all the sorted mosquito pupae by three highly trained 
laboratory technicians of IMR. 
•	 Upon completion of the field trial, responsible site management was 
imposed to ensure that the area is completely cleared of any released 
GM mosquitoes,that is the monitoring period was extended and also 
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additional fogging was to be carried out to ensure that there were no 
residue GM mosquitoes in the environment.
•	 The NBB, through the Department of Biosafety, was to closely monitor 
the implementation of the field trial to ensure compliance at every stage 
of the release.
•	 Science based issues or uncertainties highlighted by researchers well 
versed with the issue were taken seriously and included in the scientific 
assessment by GMAC. 
•	 Some of the skepticism expressed through public consultation about the 
field trial was due to lack of understanding of the science behind the 
field trial and an assumption that it is the final release to suppress Aedes 
population. Other valid concerns were considered in the assessment.
•	 Residents from the field trial site will be engaged in public awareness 
activities and information about the field trial will be made available.
The following socio-economic considerations were also taken into 
account in the decision making:
IMR has been very actively involved in GM mosquito research 
since 2006. Previous studies have already been conducted as laboratory 
experiments (contained use) and semi-field trials. This field experiment is 
the next phase of this research and is also an important prerequisite for any 
subsequent full scale release for population suppression and an important 
aspect of its capacity building plan. 
•	 Number of deaths and the cost of medication due to Dengue.
•	 New technologies should be explored to complement the integrated 
pest management programme (IPM).
•	 The suppression of Aedes population by incorporating this GM 
technology in the IPM is promising.
•	 Cayman Island has already done a field release of this GM mosquito 
and there were no issues caused by the release. 
•	 Other countries such as United States of America (Colorado), Thailand, 
Brazil and India are involved at contained use experiments involving 
GM mosquitoes. Countries like Singapore and Vietnam are reviewing 
this technology involving GM mosquitoes. Malaysia too need to move 
with the time.
•	 A Malaysian agency has ownership in the intellectual property.
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ii) Trypsin Modulating Oostatic Factor (TMOF)
The National Biosafety Board on July 26, 2011 granted approval with terms 
and conditions to an application from EntoGeneX Industries Sdn. Bhd. 
(EntoGeneX) for release activities of TMOF_Yeast. This approval permits 
the release of the “heat-killed” TMOF_Yeast containing TMOF (Trypsin 
Modulating Oostatic Factor) peptide which is formulated into Mousticide 
Rice Husk (RH) and Mousticide Wettable Powder (WP). The products 
were aimed at controlling the Aedes mosquito larvae population. The 
recommendation of the GMAC to the NBB was for an approval with terms 
and conditions in accordance with the provisions of subsections 16(3) and 
16(4) of the Biosafety Act for the use of Mousticide WP and Mousticide 
RH. This recommendation was based upon the condition that the issues 
identified in the environmental risk assessment be thoroughly reassessed for 
the accumulative impact from long-term usage of this product, or if TMOF 
is used for the formulation of another type of end product, as there may 
be variables in the effectiveness of the protocols used as well as variations 
in the risk exposure pathways. Proper risk management strategies are to be 
followed as stipulated through the terms and conditions imposed. These 
conditions include restrictions in distribution sites, such as finished, treated 
drinking water sources and also the imposition in mandatory labeling; for 
which product handling and safety instructions are to be clearly displayed. 
In addition to supporting data provided from studies done on the product, 
further studies shall be carried out, focusing on local organisms, in a 
prescribed period and the results reported back to NBB. Public consultation 
for this application was done from June 9, 2011 until July 8, 2011. Concerns 
raised by the public were addressed and taken into consideration when 
NBB made the decision. 
The following socio-economic conditions were taken into account in 
the decision making:
•	 That impact studies of the product had already been conducted by the 
Malaysian Palm Oil Board on the oil palm pollinating weevil; 
•	 That data had been provided in the Environmental Protection Agency 
(USA) report on the safety of the product. However, further studies have 
been imposed on the applicant; 
•	 That the product is intended for use to control outbreaks of dengue fever, 
which is one of the critical health issues in Malaysia; and
•	 A Malaysian company has ownership in the intellectual property. 
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Conclusion
Malaysia had its priority right to set up a working legal framework on 
handling living modified organisms. The Biosafety Act 2007 has been 
crafted with a small window on the possibilities of including socio-economic 
considerations in decision making. Though the Regulations 2010 has 
expended this consideration further, it seems it is still insufficient to create 
a framework of parameters for a comprehensive socio-economic analysis. 
Such being the case reasonable and practical approaches were taken for the 
inclusion of the same. Thus, the case studies serve as excellent examples 
of including socio-economics. However, terms and conditions imposed in 
the case studies should be closely monitored. Fast expansion in modern 
biotechnology and numerous challenges that are emerging necessitates the 
development of a simple framework for socio-economic analysis based on 
experiences in other areas. The approaches taken have made the Biosafety 
Act 2007 a workable piece of legislation. 
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Introduction
Many attempts have been made to create international protocols which 
facilitate the emergence of similar national systems for managing 
technologies, and a number of these efforts relate to biotechnology. The 
Cartagena Protocol on Biosafety is one mechanism that has sought to 
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balance at a global level the risks and benefits of modern biotechnology 
(encompassing genetic engineering, tissue and organism cloning and 
genomics). Biotechnology is a pervasive technology, which brings together 
interests from many sectors, from the product development phase to the 
product marketing, utilisation and disposal phases. Management of this 
technology at the policy and regulatory levels is, therefore, inherently multi-
level and multi-actor, and this brings both challenges and opportunities for 
policy actors. Across Africa, there have been many efforts since the early 
2000s towards developing and implementing similar biosafety systems. 
There are many individual, institutional, sectoral, national, regional and 
international players in these efforts and their multiplicity and varying 
levels of involvement in the issue in space and time brings many dynamics 
to these efforts for the countries. 
From an analysis of the ways through which three supranational 
organisations, the New Partnership for Africa’s Development (NEPAD), 
African Union (AU) and the Southern African Development Community 
(SADC) are influencing cross-national biotechnology policy convergence 
or harmonisation processes in southern Africa, it was observed that there 
are different understandings of these concepts within various actor groups, 
with potential impact on progress towards the envisaged cross-national 
similarity in biosafety systems. The purpose of this article, therefore, is to 
advance and discuss the implications of these multiple and fluctuating 
understandings on progress towards policy similarity and on established 
theoretical perspectives within realms pertinent to policy studies such as 
systems, institutions, regimes, actor coalitions and networks. 
Following this brief introduction, the rest of the article continues 
with an overview of biosafety processes in southern Africa, and then gives 
some theoretical perspectives on policy convergence followed by a brief 
overview of the data gathering methodology used. Empirical results are 
then presented, analysed and discussed, followed by some conclusions.  
Biosafety Frameworks: From National to Regional Levels 
Biosafety, defined broadly as the safe application of biotechnology, is 
regulated at the global level through the Cartagena Protocol on Biosafety 
(CPB or the Protocol), which is a Protocol of the Convention on Biological 
Diversity (CBD). The CPB was adopted by the Conference of Parties to 
the CBD on January 29, 2000 (UNEP 2006). Even before the advent of 
the CPB, there were many efforts the world over to build regulatory and 
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technical capacity in countries for the development and enforcement of 
mechanisms for safe use of biotechnology. Policy development models used 
elsewhere in the world have been used by governments and organisations in 
developing countries in their process (e.g. the ISNAR and UNEP models and 
the African Union Biosafety Model Law, cf. Paarlberg 2000). Completion of 
policy development has been slow though. Looking specifically at southern 
Africa, only five out of the 15 countries in the SADC region have managed 
to put in place functional biosafety systems in the last 10 years (Mumba1 
personal communication 2007; SADC 2004; NEPAD-ABNE 2012).  These 
five are South Africa (1997), Zimbabwe (1998), Mauritius (2002), Malawi 
(2003) and Zambia (2007). The other countries either have advanced 
drafts of legislation which are being discussed or are nearing discussion 
at parliament level (Namibia, Tanzania, Botswana and Swaziland) or still 
have draft guidelines and other preliminary documents being developed by 
committees of experts set up by government (Lesotho, Mozambique, Congo 
DR, Seychelles and Angola) (see Omamo and von Grebmer 2005; NEPAD-
ABNE 2012). Even within each category, the countries do not necessarily 
have the same policy and regulatory arrangements, and they have employed 
different approaches and mechanisms to attain that particular status, and 
the lengths of time and amount (and type) of resources2 spent to achieve 
this also differ.  
The challenges that countries face in developing and implementing effective 
biosafety systems include perennial lack of prioritisation of biosafety issues 
in national agendas, lack of financial resources and trained manpower or 
expertise in the field of biotechnology, as well as limited awareness and 
consensus on biotechnology issues among policy makers, lawyers, scientists 
and the general public (Mugwagwa 2011; NEPAD-ABNE, 20123). The limited 
number of active research programmes employing modern biotechnological 
techniques in the majority of the countries has also been seen as a hindrance 
to the development of national policies and regulations. In other words, 
there is a lack of adequate technological developments to act as a catalyst 
for development of regulatory mechanisms (Ushewokunze-Obatolu 2004 
Jaffe 2006).4
While all these developments are going on at national level, there has 
also been a number of initiatives towards convergence or harmonisation of 
biosafety systems in Africa, both at the continental level and at sub-region 
level. These initiatives are inspired by the Cartagena Protocol which sets 
global rules and regulations on the transboundary movement, transit, 
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handling and use of living (genetically) modified organisms. The AU 
developed the African Model Law on Safety in Biotechnology which was 
finalised in 2001, while the SADC developed a regional framework on safe 
handling and transboundary movement of GMOs in 2007 (see also SADC 
2003). The NEPAD promotes cross-country cooperation and co-evolution 
between technologies and policies in its Freedom to Innovate report (Juma and 
Serageldin 2007) and the African Consolidated Plan of Action for Science 
and Technology (NEPAD OST 2006). Meanwhile, some countries from 
the SADC region participated in the Global Environmental Facility/UNEP 
Biosafety Project whose different phases had different but complementary 
and cumulative objectives hinging on promoting information sharing and 
collaboration, especially at the regional and sub-regional levels and helping 
countries comply with the CPB. There other players whose activities aid 
in the thrust towards a harmonised/converged regional biosafety system 
include the Common Market for Eastern and Southern Africa (COMESA)5, 
various regional and local-level civil society organisations.
Cross-national similarity of biosafety systems is seen as desirable from 
economic, regulatory, technological and environmental view-points, with 
expectations that it will allow countries to share resources, draw lessons 
from each other, and shorten technology and product approval processes 
and also positively impact on the environment conservation efforts of 
countries (Ayele 2006). However, the motivations and compelling factors 
for policy convergence and harmonisation from international and national 
perspectives are always fluctuating, and this presents challenges to the 
feasibility of the convergence/harmonisation agenda.  
Theoretical Perspectives on Cross-national Policy Convergence
Policy convergence is broadly defined as the growing similarity of policies 
over time (Bennett 1991; Kerr 1983; and Knill 2005) and policy convergence 
studies are thus concerned with the similarity of policies as an observable 
phenomenon. Policy diffusion, transfer, learning and harmonisation are 
viewed as pathways or mechanisms towards convergence. Scholars in 
these areas are in agreement on this (see review by Heichel et al. 2005). 
It is however, acknowledged that convergence may be a result of other 
problem pressures and not necessarily the ones mentioned above (Knill 
2005).  In addition, similarity, which is the main concept fundamental to 
convergence research, is viewed as arbitrary and ambiguous. Sartori (1991) 
argues that being ‘‘similar or different is a matter of degree and the cut 
off point can be set arbitrarily’’. These ambiguities manifest themselves in 
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many ways, including how the convergence can be achieved and how to 
define the convergence.
According to Holzinger and Knill (2005), the first studies in the area 
of cross-national policy convergence date back to the 1960’s, although 
the topic itself gained further popularity in the 1990s. The growth in 
international trade and commerce brought about by developments in 
technology in the last fifteen to twenty years – commonly referred to as 
globalisation - has been mentioned as the major reason behind the increased 
interest in cross-national policy convergence studies (Faria 2002). The 1990s 
also mark the period in which issues on European integration came to the 
fore, with a number of researchers investigating the domestic impact of the 
Europeanisation drive and cooperation of European countries on matters of 
biosafety, and also the ‘transatlantic’ issues (see Holzinger and Knill 2005; 
Murphy and Levidow 2006; Wield et al. 2004). 
Studies on policy convergence have been carried out in many 
policy areas, most extensive of all being on social policy, fiscal policy, 
environmental policy and trade policy. There have also been some, but 
fewer studies on health policy, migration policy, agricultural policy and 
education policy (Heichel et al. 2005). With respect to biotechnology 
and biosafety, some studies have examined harmonisation in the EU 
(see Levidow et al. 1996). In their review of empirical studies on policy 
convergence, Heichel et al. 2005, also note that while the number of 
policy areas covered is fairly broad, a major limitation has been in the 
geographical regions covered by the studies.  The majority of the studies 
have been carried out in Europe and North America, with very few being 
carried out in Latin America, Asia and Africa. They attribute this to lack of 
available data and also to the heightened interest in Europeanisation and 
globalisation issues which are easier to examine in integrated markets. The 
authors acknowledge that it is ‘still not possible to characterise convergence 
research as a global phenomenon because [researches on] Africa and Asia, 
for example are still underrepresented …’. Even some of the key people 
championing convergence efforts in Africa have acknowledged the lack 
of academic input in the various processes taking place (John Mugabe6 
personal communication 2007). There is thus a need for processes towards 
convergence of biosafety systems in Africa to be studied and analysed. 
This will enable fuller and more detailed insights into these processes 
and empirical evidence from Africa to contribute to this growing field of 
convergence studies as well. 
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Convergence is generally accepted to be a result of many mechanisms 
which include harmonisation, coercion, diffusion and policy transfer 
(Jordan 2005; Holzinger and Knill 2005; Busch and Jorgens 2005; Seeliger 
1996). The main limitation in current literature on convergence research 
is that most of the work has focused on single mechanisms. The typology 
proposed by Busch and Jorgens is an attempt to look at a combination 
of mechanisms and to provide a framework to explain the multiple 
understandings and interpretations of the phenomenon. Lehtonen 
(2006) applied this typology to the environmental performance reviews 
(EPRs) carried out by the Organisation for Economic Cooperation and 
Development (OECD) in its member countries. He found the typology useful 
and he concluded that the mechanisms in operation, which are mainly 
social learning, socialisation, persuasion and soft coercion, are dependent 
on the fact that the OECD is an organisation without direct regulatory 
power; and also on the existence of environmental change agents in the 
member countries. Application of this typology on biosafety issues in the 
SADC region, therefore, promises to provide new insights.
A look at the reasons for, and implications of existence of multiple 
interpretations of convergence is an important component of the quest to 
understand the convergence processes. This is because from the onset, the 
divergent understandings and perspectives represent essentially why there is 
need for convergence in the first place. This is akin to the rationalist notion 
that ‘problems create the incentives for their solution’ (Haas 2004). Like 
many other policy arenas, the biotechnology or biosafety arena has a wide 
range of issues and it is hardly conceivable for there to be an organisation 
with the mission and resources to be able to tackle all the pertinent issues. 
As Haas (2004) explains:
‘‘the efficiency gains from relying on one single source of policy advice 
are more than offset by the loss of legitimacy, analytic blinders imposed 
by relying on just one institutional source … and the political doubts of 
bias …’’. 
Divergent views are thus inevitable and represent the reality on the 
ground. The purpose of this analysis is to situate the theory and the 
practice within the realities in order to enable an evidence-based decision 
formulation process. One main interest is to understand how achievable the 
convergence agenda is in the context of these divergent understandings, 
and at what cost to the holders of the different perspectives. All this takes 
place in the backdrop of an understanding that stakeholders pressures 
influence policies (cf. Chataway et al. 2006).7
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Methodology
The different meanings associated with convergence were identified largely 
based on an analysis of documents from various organisations taking part 
in efforts towards development of converged systems. Responses from 
interviews conducted among stakeholders in the SADC region and beyond 
as part of the bigger study were also carefully analysed for the different 
framings of convergence.8 An evaluation of both the formal and informal 
discourses9 on biosafety and in the broader science and technology arena 
was carried out in order to gain a wider understanding of the issue. One 
of the main difficulties with this task is that in their day-to-day work on 
biosafety issues, stakeholders hardly refer to their work in convergence 
terms, and in some cases biosafety is not a prominent issue on the day to 
day policy agendas. However, it is for these reasons that an understanding 
into the various conceptual and practical meanings of convergence was 
sought. Data analysis was done using thematic analysis (Boyatzis 1998), 
with meanings of concepts being one of the themes. 
The Emerging Understandings
USING discussion and interview results and observations from the 
interactions with stakeholders, a compilation of different meanings or 
accounts of convergence was developed. The understandings have been 
classified according to a number of factors (see Table 1).
The different understandings in Table 1 represent various dimensions 
of issues around convergence; among them being what should converge, 
who should be involved in the processes towards convergence, where 
should convergence take place, how should convergence take place and 
why should convergence take place? The characterisation as broad versus 
narrow or process-based versus output-based perspectives of convergence is 
based on the different opinions or responses to these clusters of questions. 
Narrow-focused understandings are defined as those looking at convergence 
of regulations only or the practice within the technology only, while the 
broader understandings cover both the technology, the regulations and 
pertinent issues in allied areas such as seed laws and intellectual property 
rights. Narrow-focused understandings also propose limited time scales and 
geographical scope with respect to feasibility of convergence. Process and 
output-based accounts, on the other hand, relate to the different ways of 
achieving convergence (the process) and the resultant policy or regulatory 
arrangements (the outputs). Many issues emerge from this typology and 
also from the perspectives behind this representation, and these will be 
looked at more closely. 
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Table 1: The Different Understandings/Framings of Convergence as 
Observed From Stakeholders
Description Scope Main stakeholders 
behind 
understanding
Categorisation
(Broad or 
Narrow  
focus)
Organisation 
where particular 
focus is dominant 
Output-focused10
Convergence on 
biosafety and allied 
issues
Risk regulation,
Technology 
development
Scientific R&D 
institutions
Broad focus NEPAD
Convergence on 
biosafety only
Risk regulation
Policymakers, food 
relief agencies/civil 
society organisations 
(CSOs)
Narrow focus AU, SADC
Convergence with 
respect to risk 
assessment only
Risk regulation
Policymakers, food 
relief agencies/CSOs
Narrow focus AU, SADC
Implementation at 
regional level
Collaboration 
with 
neighbouring 
countries
Regional bodies, 
scientific R&D 
institutions
Broad focus AU, NEPAD
Implementation at 
national level
Focusing on 
serving national 
interests
Relevant 
government 
departments
Narrow focus SADC
Process-focused11
Co-evolution of 
technology and 
regulations
Risk regulation,
Technology 
development
Regional bodies, 
scientific R&D 
institutions, relevant 
government 
departments
Broad focus NEPAD
Convergence on 
regulations only
Risk regulation
Policymakers, food 
relief agencies/CSOs
Narrow focus AU, SADC
Involve policy 
makers only
Focus on the top
Policy makers, food 
relief agencies
Narrow focus SADC
Involve all key 
stakeholders
Broad 
stakeholder 
consultation 
CSOs, some 
government 
departments
Broad focus NEPAD
Stepwise in terms 
of geographical 
and institutional 
coverage
Structured and 
bottom-up focus
Regional bodies, 
R&D institutions, 
policy advisers 
Narrow focus
All three reflect 
this at certain 
stages
Holistic and 
all-encompassing 
approach through 
and through
Combinations of 
approaches
Regional bodies, 
R&D institutions, 
policy advisers
Broad focus As above
39
The distinctions between the broad against narrow (or process versus 
output-based) accounts with respect to the responses to the clusters of issues 
above are not as clear-cut as shown here, and this is due to a number of 
reasons. The following are some of the reasons behind the different and 
fluctuating framings:
Unclear Understanding of Terms
On one extreme, there are policy actors who do not seem to fully understand 
the meanings of the terminologies they use and the differences between 
them and other related terms. One researcher from a scientific and 
industrial research and development institution in Zambia indicated that 
he “was confused as to whether what is required is consensus, unanimity 
or coherence …”, though he “felt the desired end is to have regulatory 
systems that speak to and understand each other”.  He also bemoaned the 
lack of arrangements to introduce and equip policy actors adequately to deal 
with challenges in the policy innovation arena. This is a serious problem in 
some cases and one of the reasons could be what Alvin Weiberg observed in 
1972 about scientists “[that] often they were asked to provide advice that 
exceeded their formal disciplinary training” (cited by Haas 2004). There is 
thus an issue of actors facing the challenge of moving, for example, from 
being policy implementers to being policy developers, without the necessary 
exposure and experience.
On the other extreme, there are some policy actors who get locked 
into certain framings and understandings, mainly to be seen to be in sync 
with current discourses, and to be able to secure funding from donors. 
This is particularly the case with process-based accounts. For example, 
multistakeholder or participatory processes seem to be the mantra for 
civil society-driven processes, and whether or not this brings the required 
efficiency may be quite another issue. The following observation in August 
2006 from one coordinator of a regional biodiversity programme in the 
SADC typifies this dilemma:
“Let’s not forget that there are two key issues here; the problems exist 
here, but they are identified (from) elsewhere, and the agenda to address 
them is set elsewhere too. So we have to comply … with the problem-
packaging and the solution-packaging.”
Rivalries, Alliances and Organisational Mandates
Contested power, competence and legitimacy issues between and among 
institutions also lead to some institutions and/or individuals wanting or 
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adopting certain framings at the expense of others. The same is also true 
where institutions want to identify with the practices in another institution, 
to the extent of adopting similar practices. There are thus understandings 
based on rivalries or alliances among institutions. For example, two leading 
supranational organisations have had their staff failing to attend meetings 
of the joint committee set up by these two organisations because of the 
fundamental conceptual differences between the two organisations. A 
respondent from one of the institutions was very emphatic that: ‘‘… this 
joint committee is just a requirement of the donors, otherwise we have no [further] 
grounds on which to cooperate’’.
The mandates and missions of different institutions have a major 
influence on how they frame the convergence issue, and this in turn 
depends on the actor coalitions around each institution and the issue 
at hand. Fluctuations within the actor coalitions sometimes result in 
fluctuations in framings. Further complications on this emanate from the 
fact that the different actors are at various vertical and horizontal levels, 
ranging from institutional, sectoral and national to international levels. 
Varying Demands on Convergence of Ideas
The level of interdependence among institutions varies considerably in 
space and in time, and this leads to constant shifts in the understandings. 
For example, in international fora (e.g. negotiations and discussions under 
the Biosafety Protocol) organisations that are ordinarily rivals within the 
region may be forced to present a unified agenda, and this causes a temporary, 
though sometimes permanent shift in the understanding. On the other hand, 
allied institutions may present divergent faces as a way of trying to develop 
some unique selling points for their programmes. One respondent from a 
policy analysis network in the SADC region indicated that: 
‘‘when all factors have been taken together, our agendas and the way 
we discern and implement processes is influenced more by providers of 
funding, than by the local policy communities we intended to serve … our 
own visions vary with those of the providers of funding.’’
Early 2006 saw southern African partners on both divides of the 
biotechnology debate participating in a preparatory meeting for the 
Cartagena Protocol on Biosafety’s Conference of Parties (COP) which was 
held in Brazil. The coming together in the preparatory meeting was possible 
because, as one senior official in a regional biodiversity management 
programme observed:
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“…a donor came along and gave the region funds to prepare that way 
so that a regional voice could be developed’ … but ‘… as it turned out, when 
we got to Brazil, everyone teamed up with their traditional international 
partners …”
Resources
Linked to the issue of mandates and missions, is the issue of resources for 
implementing programmes. Many organisations and programmes have 
to contend with a narrow remit of issues because of restricted resources. 
Resource availability thus dictates how stakeholders or clusters of 
stakeholders should understand an issue, in the process influencing what 
is deemed feasible. It is argued that availability of resources can propel 
development towards a common pattern despite disparate politics, ideology 
and culture (McGaughey and Cieri 1999). In fact, respondents highlighted 
the issue of resources as both the biggest hurdle to, and determinant of the 
potential path to be taken by policy processes. 
Mobility of Policy Actors
Then there is the issue of policy actors moving from one policy arena to 
another, either in pursuit of new employment opportunities, or as part of 
the routine ‘surfing’ to fill capacity gaps (cf. Hilgartner and Bosk 1998). 
This not only leads to a continual fluctuation of the understandings of the 
issue among groups of actors, but further blurs the distinctions between 
the different categorisations of understandings. Policy actors also find 
themselves not having enough time to adequately prepare for, or consider 
issues, as one respondent from a national farmers’ union indicated:
“…being in this position can be distressing sometimes, as I have to deal 
with many issues, from HIV/AIDS, climate change, pollution, and then this 
(biosafety and biotechnology). And I have to represent my organization on 
all these issues. Coping with the demands is never easy, especially keeping 
up with the latest developments. Half-baked jobs are the order of the day.”
In addition to the above challenges emanating from capacity constraints, 
there are country-specific conditions that influence understandings towards 
certain policy positions/conceptualisations. Appreciation of these drivers is 
crucial for shaping interventions within the multi-actor arena. For example, 
there are countries which have a long tradition of being risk-averse (e.g. 
Zambia12) and always waiting for technologies to mature before they can 
take them on board. Such countries are, not surprisingly, more towards 
the narrow, country and biosafety-centric measures. A country’s or an 
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institution’s capacity to create, acquire, accumulate, diffuse and utilise 
scientific knowledge also has a strong correlation with the breadth of their 
understanding of the issue, although the leadership influence of some 
countries and institutions may have a confounding effect.
Linking Back to the Technology
The scope of issue framing within the technology arena also influences 
how policy convergence is framed. Schattschneider (1960) discusses policy 
entrepreneurs engaging in ‘venue shopping’, that is, searching for arenas 
from which to frame policy problems, and that the policy entrepreneurs 
may themselves ‘limit the venues in which they set their feet’. For example, 
taking science only as a policy venue, the leeway for venue shopping is likely 
to vary across countries, across other sub-national arrangements, and among 
policy actors (Renn 1995). Different actors may seek access to different 
types of venues (Pralle 2003), and this illuminates how public problems are 
a result of successful imposition of problem definitions by one group on 
others (Hajer 1995). In the SADC region, for many policy actors, biosafety 
is about safe application/use of products of modern biotechnology, while to 
others, it is about ensuring safety of all ‘biological’ processes and products 
(Kelemu et al. 2003). Science and scientific knowledge are key venues in 
both cases, but the extent to which these are explored and incorporated 
in the science-policy nexus differs because of the different levels of focus 
on the science. These different framings result in what Schattschneider 
referred to as issues being “organised into or out” of politics. In the final 
analysis, this has a bearing on both the process-based and the output-based 
accounts of convergence.
Analysis and Interpretation of the Emerging Understandings
This issue of cross-national policy convergence, looking specifically 
at biosafety in the SADC region, looks into a number of practical and 
theoretical perspectives around convergence. These include international 
relations, organisational and institutional theories, coordination theories 
(for example, the game theory model) and systems theory, among many 
others.   This essentially reflects the broad, all-encompassing and integrative 
nature of biotechnology/biosafety issues, and the various forces at play 
in the social construction of public problems. However, this analysis has 
narrowed down to a few perspectives given the main force behind these 
multiple understandings, that is, the movement of actors within the 
policy arena. These understandings are also being influenced by the issue 
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of resources, and the expectations of resource inflows as well as speedy 
implementation of activities which are stimulated by how the issue is 
framed. 
One issue that seems to emerge in practice as a result of these multiple 
understandings is the proverbial “too many cooks … spoiling the broth”. 
This manifests itself in a number of ways, for example, some aspects within 
the full integrative range of issues around biosafety are left unattended as 
actors jostle to occupy arenas that attract funding, and from which they 
can easily make an impact. This is why, for example, many organisations 
tend to occupy the information dissemination arena where it is easier to 
leave a mark. Concurrently, the same organisations will be looking around 
and believing that someone among the many other players will take up the 
remaining issues. A number of gaps also exist within both the vertical and 
horizontal dimensions of the issue (Shaffer and Pollack 2004). Often this 
is not because the information or other attributes to fill those gaps are not 
there, but because of a lack of obligation among the various players to take 
forward what the player at the other level (lower or higher) has done. This 
issue is best explained within the social arena of problems (cf Hilgartner 
and Bosk 1998), where multiple perspectives may not overlap enough to 
cover the issue area adequately. 
While talking about the teaching of the so-called new and ‘authentic 
science’ (as opposed to traditional science), Roth (2001) alludes to 
enculturation that may lead to the acquisition of conceptual blind spots 
and prejudices as a result of trying to get students “to do the real stuff”. 
The desire to want to “move with the time” with respect to issues within 
the discourse on a given issue sometimes leads to an exclusion of other key 
considerations, leading to poor delivery at the end of the day. Ray Dart13 
(2006) also talks about such blinds spots in the non-profit strategy process, 
where emphasis is placed on organisational and programme strategy, leaving 
out change models and intervention strategies. It is crucial that when the 
different understandings of convergence are brought together, such blind 
spots are minimised. 
The public arenas model on the rise and fall of social problems 
(Hilgartner and Bosk 1998) looks at the issue of stakeholders “jumping” 
from one policy domain to another, and also how dramatisation is crucial 
in getting a policy issue to attract attention in the midst of competing 
interests. These perspectives are crucial in explaining and understanding 
what is happening in the issue at hand, and in devising an appropriate way 
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forward. In biosafety the particular challenge is on how the issues come 
together at regional level, bearing in mind that the dynamics are different 
from those at national level. There is problem amplification beyond 
predictable levels. Issue novelty and policy arena saturation dynamics also 
vary as different jurisdictions are brought together. This inevitably leads 
to different understandings of the issue at hand. The public arenas model 
of looking at the rise and fall of social problems can thus provide useful 
insights in the dynamics of framing the biosafety policy convergence 
problem. One of the key questions, therefore, remains how one dramatises 
an issue which is at different agenda levels in space and time, ensuring 
consistency of meaning at the different levels. 
There is also a wave of expectations created around the different issue 
framings. A combination of the framings and the new technology creates 
an even higher sense of expectation amongst the intended beneficiaries 
of the planned interventions. Expectations play a crucial role in resource 
mobilisation and galvanising actor groups (Borup et al. 2006). It is, therefore, 
important that these different understandings, and the expectations they 
elicit among stakeholders are understood, so that the envisaged purpose 
of bridging or mediating across different actor boundaries and levels 
can be better managed. It is also important to note that some kind of 
a prisoner’s dilemma exists amongst the different stakeholders and the 
interpretations that they hold. Stakeholders are not sure what impact their 
independent pursuit of self-interest (that is, their framing of the issue and 
the attendant implementation mechanisms) will have on the bigger policy 
community of which they are only a part. As a result, actor communities 
may find themselves undecided on what route to take given the various 
and fluctuating forces around the issue. Consultation among the different 
stakeholders and feedback on their interpretations of the policy process 
are, therefore, crucial in building synergies.  
Conclusion
The article has highlighted that what may appear to be mere differences in 
semantics, or different expressions of the same desire, may in the long run 
have telling impacts on how “visions” or “imaginings” can be translated 
into tangible outputs at the policy level. In the final analysis, therefore, 
the challenge is to try and understand the ways in which these fragmented 
perspectives may eventually come together towards the envisaged 
collective action. In other words, is it possible for convergence to occur 
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in the backdrop of multiple understandings of convergence? This has an 
implication on how the convergence can be achieved, and how sustainable 
the converged systems will be. Do the different understandings at some 
stage have to pave way for a consensus position? 
Social constructivists have shown that “various actors are likely to hold 
different perceptions of what the problem really is”. However, as Hajer 
(1995: 44) alludes to in an analysis of discourse around environmental 
dilemmas, it is important to ‘understand why a particular understanding of 
the environmental problem at some point gains dominance and is seen as 
authoritative, while other understandings are discredited.’ While the article 
has presented and analysed the different ways in which the biotechnology 
policy convergence problem is presented, and the emergence of social 
coalitions around specific understandings, the issue of how coherence 
emerges from these differences is an important subject in its own right. 
The social-constructivist rejection of the “single problem-single answer” 
model (Hajer 1995:43) is key in understanding how the various perceptions 
then come together.  
Knowledge of the different understandings of convergence is crucial, 
not for the sake of eliminating differences between these understandings, 
but in order to present evidence of these existing realities to the policy 
making process. The prevailing understandings of policy convergence in 
biotechnology or biosafety in southern Africa region are influenced by a 
number of issues ranging from organisational institutional missions and 
mandates, organisational and individual capacity issues, resource-related 
issues, and the ever-present challenge of legitimacy which confronts 
policy processes. This discussion has looked at how these issues are at play 
and how it is in the best interests of both policy actors and researchers to 
understand the context as a way towards ensuring a better link between 
policy discourses and practice.
Endnotes
1 Prof. Luke Mumba is the Director of the Southern African Network on Biosciences 
(SANBio), one of the four subregional networks for the NEPAD’s African Biosciences 
Initiative (ABI).
2 Resources here include policy/legislation models used as well as the common financial, 
human and other material resources.
3 http://www.nepadbiosafety.net/for-regulators/resources/subjects/biotechnology/status-of-
crop-biotechnology-in-africa (accessed September 14, 2012)
4 This techno-centric view is shared by many scientists in the region, while those less 
optimistic, notably anti-biotech lobbyists feel the issue needs to be looked at within the 
bigger macro context of individual countries and the region.
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5 COMESA and its partners are currently at advanced stages in the development of a regional 
biotechnology policy to guide decision-making on commercial planting, trade and GM-
food aid. (ISAAA, May 2012: http://www.isaaa.org/kc/cropbiotechupdate/article/default.
asp?ID=9602) 
6 Prof. John Mugabe is a former Director/Advisor of the NEPAD Office of Science and 
Technology.  
7 Stakeholders ‘loyalty’ to policy agendas when their issue framing is ignored or sidelined is 
part of the investigation in the bigger research.
8 The respondents included regulators/policy makers, NGO workers, scientists, research 
managers/administrators, representatives of international development partners and staff 
from the three supranational organisations. Study was conducted between 2006 and 2008, 
with further data being collected in 2010 and 2011. 
9 ‘Formal’ refers to discussions or issues raised while respondents were speaking in their 
official capacities (e.g. in meetings/workshops, interviews, etc.) while ‘off-the-record’ or 
personal views and other opinions outside the official setting are referred to as ‘informal’. 
10 Referring to the policies/regulatory systems. 
11 Referring to the path being followed to come up with the policies or regulatory systems.
12 As indicated by one respondent from a news agency in that country, and echoed by a scientist 
from a national research institution. 
13 Ray Dart, Paper Number PA061238, Trent University, Peterborough, Canada. 
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Biotechnology, particularly plant and animal biotechnology, is perceived 
differently by different cultures because of different assessments of its 
prospects and its ethics.1
Many people, societies and States express concern over the social and 
economic changes that will accompany the widescale use of biotechnology 
and its products. It is not a visible part of the international development 
agenda primarily because of the controversy surrounding the potential risks 
of living modified organisms (LMOs) to biodiversity and human health, 
as well as the potential relevance of LMOs for traditional farming sectors 
in developing countries.2
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Chapter 16 of Agenda 21 on the environmentally sound management 
of biotechnology provides the following context:
Like with most new technologies, research in biotechnology and the 
application of its findings could have significant positive and negative socio-
economic as well as cultural impacts. These impacts should be carefully 
identified in the earliest phases of the development of biotechnology in 
order to enable appropriate management of the consequences of transferring 
biotechnology.3
As a result, many countries that are adopting biotechnology insist on 
using a decision-making process that looks beyond the narrow range of 
impacts covered by the scientific risk assessment of a specific LMO. Deciding 
what is right or permissible in relation to biotechnology in many contexts 
requires bringing together the knowledge established by a scientific risk 
assessment of an LMO with socio-economic information on that society 
and its culture.  This is a reflection of the fact that when considering the 
use of new technologies, scientific, ethical, and social issues cannot be 
wholly separated from one another.4 Socioeconomics, as a discipline, begins 
with the assumption that economics is not a self-contained system but is 
embedded in culture, government, and society. It does not assume that 
interests are necessarily complementary and harmonious, and recognises 
that societal sources of order are necessary for markets to function efficiently. 
It also recognises that individual choices are shaped by values, emotions, 
social bonds, and moral judgments rather than presuming that people act 
rationally or pursue only their self-interest or pleasure.5
The Cartagena Protocol allows Parties to take socio-economic 
considerations into account in biosafety decision making through Article 
26, which reads:
1.   The Parties, in reaching a decision on import under this Protocol or 
under its domestic measures implementing the Protocol, may take into 
account, consistent with their international obligations, socio-economic 
considerations arising from the impact of living modified organisms on 
the conservation and sustainable use of biological diversity, especially 
with regard to the value of biological diversity to indigenous and local 
communities.
2.   The Parties are encouraged to cooperate on research and information 
exchange on any socio-economic impacts of living modified organisms, 
especially on indigenous and local communities.6
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Biosafety risk assessment, described in greater detail in Chapter 4, 
aims to ensure that decisions about policies and activities pertaining 
to the development of biotechnology are taken with an understanding 
of the potential adverse impacts to the conservation and sustainable 
use of biological diversity, as well as risks to human health. In this 
light, socio-economic information is needed to provide a more 
complete picture of the impact of biotechnology. An assessment of 
environmental, social, and economic impacts in biosafety decision 
making would be more consistent with the sustainable development 
principle of integration and interrelationship of social, economic, and 
environmental objectives.7
Application of the principle of public participation, discussed in greater 
detail in Chapter 7, in this context suggests that a country’s policy about 
the use of biotechnology ought to be determined in consideration of the 
views and participation of a well-informed public.8 Such an approach is 
reflective of responsive, transparent, and accountable governance and is 
informed by the human  right to hold and express opinions and to seek, 
receive, and impart ideas; the right to access appropriate, comprehensible, 
and timely information held by governments and commerce on economic 
and social policies about the sustainable use of natural resources and the 
protection of the environment; and the right to access to effective judicial 
or administrative procedures to challenge unsatisfactory decisions and 
seek compensation.9
The inclusion of socio-economic considerations in the Cartagena 
Protocol allows for the creation of a decision-making process for biosafety 
that can be tailored to a broad range of States, societies, and cultures, so long 
as the measures taken are consistent with its other international obligations. 
It is also reflective of several sustainable development law principles, 
such as integration and interrelationship, common but differentiated 
responsibilities, the precautionary approach, public participation, and 
good governance.10
This chapter focuses on Article 26 of the Cartagena Protocol, fleshing 
out its meaning through its negotiating history, potential role in biosafety 
decision making, and the precepts of sustainable development law. The 
first section discusses the negotiations and the legal text of Article 26. 
The second section considers the role of socio-economic considerations 
in biosafety regulatory regimes. The third section describes the nature of 
socio-economic considerations in light of the principles of sustainable 
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development law. The chapter concludes with a discussion of how the use 
of socio-economic considerations in biosafety could be promoted as a tool 
to support sustainable development.
Socio-economic Impacts and Biosafety
Negotiations on biosafety following the entry into force of the Convention 
on Bio- logical Diversity (CBD) brought up many differing views on the 
socio-economic impacts of LMOs and considerations relevant to biosafety 
decision making. At the first meeting on biosafety under the aegis of the 
CBD, the 1995 Madrid Group of Experts on Biosafety, no consensus could 
be reached between Parties on whether socio-economic considerations 
should be a part of biosafety decision making.11 With the receipt of the 
Madrid Group’s report, the second Conference of the Parties to the CBD 
(COP 2) launched the Open-ended Ad Hoc Working Group on Biosafety 
(BS-WG) to negotiate a protocol and where socio-economic considerations 
would be discussed further.
At the first meeting of the BS-WG (BS-WG 1), most developed countries 
argued that socio-economics had little place in biosafety decision making 
and that including such considerations in the Protocol was not worthy 
of further study.12  Many developing countries disagreed, because they 
believed that “in addition to economic impacts such as income distribution, 
the negative socio-economic impacts of LMOs could include erosion of 
agricultural and other biological diversity; risks to sustainable use of existing 
biodiversity; and the threats of transgenic animals and plants to the cultural 
and religious order of some countries.”13  The outcome of BS-WG 1 was 
a request that the Secretariat prepare a bibliography on both the positive 
and negative socio-economic impacts of biotechnology for consideration 
at the following meeting.14
At BS-WG 2, the bibliography prepared by the Secretariat was considered 
alongside the written submissions of governments. The African Group 
proposed the most comprehensive provisions on socio-economic factors, 
which were incorporated into the draft provisions on objectives, general 
obligations, notification, risk assessment and management, and liability 
and compensation. The African Group’s draft article on socio-economic 
considerations noted the time before impacts are felt and proposed a 
seven-year notification period prior to the export of LMOs, while also 
containing an extensive list of considerations for risk assessment. This list 
included anticipated changes in existing social and economic  patterns; 
possible threats to biodiversity, traditional crops, or other products; impacts 
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caused by the replacement of traditional crops, products, and indigenous 
technologies through modern biotechnology; anticipated social and 
economic costs resulting from loss of genetic diversity, employment, market 
opportunities, and the livelihoods of communities; disruptions to social 
and economic welfare; and possible effects contrary to the social, cultural, 
ethical, and religious values of communities.15  Bolivia’s submission noted 
that the sustainable use of biodiversity, particularly domesticated plants 
and animals, depends on the socio-economic conditions of the people 
who have developed and conserved them for generations, and that the 
introduction  of genetic engineering technologies and LMOs into countries 
with rich biological and genetic diversity can result not only in the depletion 
of that diversity but also threaten the economic situation of people who 
rely on biodiversity, which could lead to discontinuation of the traditional 
agricultural systems and a loss of genetic diversity.16  On the other hand, 
Canada, the European Union, and Japan all weighed in against addressing 
socio-economic considerations in the Protocol.17
Governments submitted draft text prior to BS-WG 3 and the submissions 
of the African Group, Cuba,  India, Madagascar, Malaysia, and Sri Lanka all 
included reference to socio-economic considerations.18  It was agreed at that 
time that socio-economic considerations would not be further researched, 
but rather included in the consolidated text of draft articles with the texts 
already submitted by governments set out as options.19  A number of 
substantive options were drafted for consideration. The first reflected the 
submission of the African Group to BS-WG 2. A second option called for 
socio-economic imperatives to be considered at all levels in the Protocol 
and that particular attention be paid to the displacement of particular 
agricultural resources, cultures, or livelihoods, and to the prevention and 
mitigation of possible adverse effects. A third option acknowledged the 
considerable variation in socio-economic considerations among Parties 
and encouraged further research.20
Negotiations on socio-economic considerations from this point forward 
were very difficult. The debate mainly centered on the need to include socio-
economic considerations in the text of the Protocol at all. Many developing 
countries thought the issue was central to the Protocol, while developed 
countries found the concept too vague and country specific to have its own 
provision.21 The text and options were reduced over the course of BS-WG 
4 and BS-WG 5 to one heavily bracketed compromise provision which 
referred to the prevention and mitigation of socio-economic impacts, the 
assessment and management of risks with a long observation period, and 
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encouraging further research on the topic. In addition, it called for Parties 
exporting LMOs-FFP to notify receiving Parties sufficiently in advance to 
allow appropriate measures to be taken, providing special assistance in 
cases involving developing countries.22  Despite sympathy for the subject, 
countries could not agree about the need, place and the manner of handling 
the issue. Because of its bearing on the scope and other provisions for 
the Protocol, it was necessary for delegations to carefully consider their 
positions before BS-WG 6.23
The Chair’s proposed text at BS-WG 6 significantly modified the draft 
option, providing only that Parties should take into account socio-economic 
implications of adverse impacts of LMOs, also taking into account human 
health, especially for indigenous and local communities (ILC) as referred 
to in Article 8(j) of the CBD. It also encouraged Parties to cooperate on 
research and information exchange, including early warning to ILC that 
may be affected economically.24
The text was further revised and amended before being transmitted to 
the First extraordinary meeting of the Conference of the Parties (ExCOP). 
First, countries added a requirement that import decisions be consistent 
with international obligations. Second, socio-economic considerations 
arising from the impact of LMOs was allowed, rather than only those linked 
to adverse impacts. Third, reference to human health was deleted. Fourth, 
the value of biological diversity to indigenous and local communities was 
added rather than a blanket reference to Article 8(j). Fifth, the general 
reference to research and information exchange on any socio-economic 
impacts of LMOs, especially on ILC, replaced earlier language on early 
warning and economic effects to those communities.  Sixth, references 
to socio-economic considerations were removed from Annex II to the 
Protocol.25 At the ExCOP, a final addition was made during informal 
consultations, allowing countries to address socio-economic considerations 
in domestic measures to implement the Protocol.26
As demonstrated by its history, Article 26 was the result of intense 
negotiation and compromise and is rather limited when compared to some of 
the legal text initially proposed by developing countries. Like the remainder 
of the Protocol, it represents a balance between the interests of industrialised 
and developing countries. Through this compromise, industrialised countries 
and their biotechnology sectors can be assured that scientific risk assessment 
remains the primary basis for biosafety decision making, while developing 
countries are also assured that socio-economic considerations can be relied 
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upon for some decision-making processes. To bring clarity to the terms of 
Article 26, the particulars of biosafety decision-making and the relevance of 
socio-economic considerations are discussed below.
Biosafety Regimes and Socio-economic Considerations
The main basis for biosafety decision making is scientific risk assessment.27 
The focus of scientific risk assessment is on the possible environmental and 
human health impacts of a new organism or its products, many of which 
can be measured by traditional scientific techniques. Opinions vary about 
the value and desirability of including socio-economic considerations in 
decision-making processes and the introduction of broader socio-economic 
considerations into biosafety analysis.28
Understanding the impacts of modern biotechnology and its products 
and processes in the context of sustainable development  requires looking 
beyond the physical sciences. New crops and new foods have a trenchant 
impact on societies across the globe. Their socio-economic effects are as yet 
undetermined but can be positive, negative, or neutral, and can be expressed 
by a variety of actors. Some of the concerns are relevant to numerous actors, 
whereas others are discrete, belonging to a particular group. Some of these 
concerns are common to both developed and developing countries, whereas 
others are relevant only to one or the other. Socio-economic impacts are 
not unique to biotechnology, but taking them into consideration is of 
particular relevance given the rancorous debate over this technology. The 
International Law Association’s Hague Recommendations on International 
Law on Biotechnology suggests accommodating a range of legislative 
responses while also considering different levels of social and economic 
development.29
The limited scope of Article 26 is important  to recognise. First, the 
wording of Article 26(1) limits the use of socio-economic considerations in 
biosafety decision making to those arising from the impact of LMOs on the 
conservation and sustainable use of biodiversity.30  This can be interpreted 
to mean that where the introduction of LMOs under the Protocol 
affects biological diversity with potential or actual social and economic 
repercussions, Parties can justify taking into account such impacts when 
making decisions on LMO imports or in implementing domestic measures 
under the Protocol.31  Second, the provision gives particular recognition to 
socio-economic considerations arising from the value of biological diversity 
to indigenous and local communities.
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Socio-economic considerations beyond the Cartagena Protocol are 
those that concern  products or activities falling outside the mandate  of 
the Protocol, such as socio-economic considerations related to organisms 
that do not fall within the definition of LMO, living organism, or modern 
biotechnology as used in the Protocol; considerations related to LMOs that 
are not subject to the activities covered by the Protocol (that is, domestic 
or non-transboundary movement, transit, handling, and use); impacts of 
LMOs beyond the conservation and sustainable use of biodiversity; and 
LMOs that are pharmaceuticals for humans and are addressed by other 
international agreements or organisations. Countries can implement 
biosafety regulatory regimes that encompass socio-economic concerns 
beyond those included in the Cartagena Protocol if their regulatory system 
complies with any other international obligations by which they may be 
bound. In the context of the AIA and LMOs-FFP procedures for import/
export, socio-economic considerations can be used by the importing Party 
as a basis for decision at that stage.32
A literature survey reveals a broad range of sometimes conflicting 
socio-economic considerations relating to GMOs and LMOs. Careful 
research to clarify the socio-economic issues related to biotechnology 
is essential but is not in itself sufficient to incorporate socio-economic 
considerations into biosafety decisions. Practical steps are necessary for 
these considerations actually to be taken into account when decisions 
are made. These steps might include  policies that mandate  integration 
of socio-economic considerations into decision-making processes; a clear 
definition of “socio-economic considerations” and explicit criteria to 
determine  when  and where socio-economic assessments are required; 
identification of the stages at which socio-economic assessments should 
take place; efficient and cost-effective regulatory processes; and public 
participation mechanisms to ensure credible assessments and more widely 
accepted decisions.33 The following methods have been proposed for taking 
socio-economic considerations into account: procedures for assessing and 
addressing socio-economic impacts in risk assessment and management, 
and subjecting decisions on import of LMOs to prior public consultation 
processes, especially with respect to communities directly affected by the 
import decision, for example the local community in which the LMO is 
destined for field trial or use, or that could be affected by any potential 
adverse impacts of the LMO on biodiversity.
In 2007, UNEP-GEF received funding from the U.K. Department  for 
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International Development to undertake a scoping exercise on socio-
economic considerations in biosafety decision making. The exercise 
included an information-gathering survey on countries’ experience 
with socio-economic considerations undertaken in cooperation with 
the SCBD.34  At UNEP’s request, the summary report was circulated as an 
information note for participants at the fifth Conference of the Parties to 
the Convention on Biological Diversity serving as the meeting of the Parties 
to the Cartagena Protocol (COP-MOP).35  The responses are instructive of 
how socio-economic considerations can or should be addressed as a part 
of the biosafety regulatory regime.
The survey first asked respondents their opinion on the importance 
of including socio-economic considerations in decision making on LMOs 
in their country. Eighty-five per cent indicated that socio-economic 
considerations were either very important or somewhat important, with 
four-fifths selecting “very.”36  Of the countries having a decision-making 
system for LMOs in place, two-thirds of respondents stated that it was able 
to take socio-economic considerations into account.37
In those countries where socio-economic considerations were addressed 
in the decision-making system, most of respondents indicated that the 
regulatory framework addressed the concept in a general fashion, some 
indicated that socio-economic considerations were treated on an ad-hoc 
or case-by-case basis without any explicit inclusion in the decision-making 
system, and the least number identified socio-economic considerations 
as being covered through the assessment of particular elements during 
specific steps in the process.38 The largest group of responses on how best 
to incorporate socio-economic considerations into the decision-making 
process was in favour of a specific, identifiable mechanism; the next largest 
group supported a general framework for application within the risk 
assessment process; some respondents supported a participatory process that 
included a broad spectrum of stakeholders; a few respondents supported 
an ad-hoc or case-by-case approach; and a small number of respondents 
were against including  socio-economic considerations in biosafety decision 
making.39
The top five socio-economic issues of importance in all countries with 
a biosafety system were identical: food security, health-related impacts, 
coexistence of LMOs and non-GM agriculture, impact on market access, 
and compliance with biosafety measures. More variation occurred with the 
importance of the next five issues, and depending on ranking, the following 
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issues arose: conservation and sustainable use of biodiversity; economic 
impacts of changes in pest prevalence; macroeconomic impacts; farmers’ 
rights; intellectual property rights (IPRs); impacts on consumer choice; 
economic impacts of changes in the use of pesticides and herbicides; and 
impacts to indigenous and local communities.40
Countries with a biosafety decision-making system had several different 
ways of considering socio-economic considerations in the decision-making 
process. An assessment that happens during the risk assessment stage was 
identified most frequently, followed by an equal proportion of “prior to the 
risk assessment” and “after the risk assessment.” During the appeal, review 
or renewal of the permit was identified the fewest number of times.41 Lack 
of a mechanism for including socio-economic considerations in decision 
making and lack of capacity were identified as important reasons why 
assessment was lacking from the decision-making system. Human resources 
and informational and financial challenges were identified as challenges 
to the inclusion of socio-economic considerations in decision making. 
Capacity building and the development of guidelines are thus important 
mechanisms that could decrease the challenges to and the reasons for not 
including socio-economic considerations in biosafety decision making.42 
Many countries have adequate capacity to perform socio-economic 
assessments, but most answered “do not.” It is also clear, however, that once 
decision-making systems are put  in place to account for socio-economic 
considerations, skill levels increase, meaning  that increasing the capacity 
for socio-economic assessment could increase the number  of countries 
that take socio-economic considerations into account in their decision-
making processes.43
Several conclusions can be drawn from this. First, socio-economic 
considerations can be taken into account in the decision-making process 
if countries want to do so. Second, once countries start to incorporate 
them, they can do this across decisions, across multiple organisms, and 
across intended uses of the organism.44 The current practice for including 
socio-economic considerations in most countries seems to be for one 
entity to assess socio-economic considerations and a different entity to 
evaluate the assessment. Three forms of government entity are most often 
involved in assessment and evaluation: the national competent authority, 
a multisectoral committee, and/or a government committee consisting of 
several departments.45 Although there seems to be a strong consensus that 
socio-economic considerations should be taken into account, it is less clear 
how and where socio-economic information should be used. There was the 
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strongest support for the consideration of socio-economic information at 
the same time as scientific risk assessment information in the biosafety 
decision-making process, far less support for considering socio-economic 
information after scientific risk assessment information, and a split between 
whether socio-economic information should be evaluated separately 
from the scientific risk assessment or incorporated into the scientific risk 
assessment.46
A great degree of uncertainty exists over how socio-economic 
information can be used in biosafety decision making and the weight 
that it should be assigned.47 The capacity to undertake and evaluate socio-
economic assessments in biosafety decision making varies greatly. Countries 
that consider socio-economic information in their decision-making systems 
score high in terms of having people with skills, professional training, or 
experience to undertake and evaluate that information. Most countries 
lack adequate capacity to perform socio-economic assessments and might 
be reluctant to establish a decision-making system depending on socio-
economic information.48
Countries are in need of capacity building on socio-economic 
assessment capacity and are seeking a methodologic guide or toolkit on how 
to undertake socio-economic assessments as a means to start the capacity-
building process.49 Elements that should be considered in biosafety decision 
making must be identified.50
A consensus is forming on the important socio-economic issues 
and priority areas for capacity building. The socio-economic issues that 
respondents identified as priorities for capacity building are similar to 
the socio-economic issues being considered in existing decision-making 
systems. This will facilitate capacity building and provide guidance  on 
the material to be included  a methodologic toolkit.51 Further research 
is needed to show how particular socio-economic considerations can be 
used to address the priority areas of concern for capacity building and 
sustainable development.
Biosafety, Socioeconomics, and Sustainable Development Law
The social aspect of sustainable international biodiversity and biosafety 
law is the least developed aspect in national and international law.52 This 
aspect overlaps other areas of sustainable development law, such as the 
right to food, access to medicines, the right of access to innovations, and 
corporate social responsibility (CSR). The following section elaborates on 
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the socio-economic aspect of the Cartagena Protocol in the context of 
emerging principles of sustainable development law.
Principle of Integration and Inter-relationship
In accordance with the principle of integration,53 the Protocol recognises 
that economic and social development considerations can be pertinent to 
biosafety decision making in addition to the environmental  considerations 
raised by scientific risk assessments. Specifically, it complies with the 
emerging customary norm of integration, in that the Cartagena Protocol 
requires States to “ensure that social and economic development decisions 
do not disregard environmental considerations, and not undertake 
environmental protection without taking into account relevant social and 
economic implications.”54 Because of its recognition of socio-economic 
considerations as a fundamental basis for biosafety decision making, the 
Cartagena Protocol can be categorised as a highly integrative treaty.55
The Cartagena Protocol also reflects the interdependence of the needs 
of current and future generations. The socio-economic impacts of modern 
biotechnology will be far ranging and affect States from this point on in 
history. This should be implemented at all levels of governance, because it 
is essential to the achievement of sustainable development.56  The  principle 
also calls for States to resolve apparent conflicts between competing 
imperatives through existing and appropriate new institutions,57 including 
the WTO and the Codex Alimentarius, for example. Countries that include 
socio-economic considerations alongside environmental risk assessments in 
their biosafety systems also will be creating sustainable development law. 
Some different ways to include the socio-economic dimensions of biosafety 
in a domestic regulatory system offer differing degrees of integration.
Principle of Sustainable Use of Natural Resources
Under the principle of sustainable use of natural resources, States may 
manage natural resources pursuant to domestic environmental and 
developmental policies.58 Integrating socio-economic considerations into 
biosafety decision making plays an important role in determining whether 
the impacts of biotechnology on biodiversity are sustainable given the 
potential social and economic costs/benefits. This right is limited by the 
second component  of the principle, the requirement  that states must not 
cause irreparable damage to the territories of other states, or increasingly, 
the global environment.59 States are under a related duty to manage 
natural resources in a rational, sustainable, and safe way to contribute to 
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the development of their peoples, with particular regard for the rights of 
indigenous peoples, and to the conservation and sustainable use of natural 
resources and the protection of the environment,  including  ecosystems.60 
The  specific language of Article 26 of the Cartagena Protocol maps directly 
onto this duty and is an excellent example of the principle in action. 
Complicating the principle’s application is the requirement that States 
consider the needs of future generations in determining the rate of use 
of natural resources, and the related duty of all relevant actors (including 
States, industrial concerns, and civil society) to avoid wasteful use of 
natural resources and promote waste minimisation  policies.61  Integrating 
socioeconomics into the biosafety decision-making process can account 
for the needs of future generations and help to implement the duty of all 
relevant actors to avoid waste and promote waste minimisation. Ultimately, 
the integration of socio-economics is of particular importance because 
centres of origin and centres of genetic diversity are of crucial importance to 
humankind, and the conservation and sustainable use of biologic diversity 
is a common concern of humankind.62
Principle of Equity and Elimination of Poverty
The principle of equity and poverty elimination could significantly 
inform the use of socio-economic considerations in biosafety decision 
making. This principle refers to both intergenerational equity (the right 
of future generations to enjoy a fair level of the common patrimony) 
and intragenerational equity (the right of all peoples within the current 
generation to fair access to the current generation’s entitlement to the 
earth’s natural resources).63 The present generation has a right to use and 
enjoy the earth’s resources but is obliged to take into account the long-term 
impact of their activities and to sustain the resource base and the global 
environment for the benefit of future generations of humankind. Benefit 
in this context should be understood in its broadest meaning, economic, 
environmental, social, and intrinsic benefits. Intergenerational equity 
requires the present generation not to introduce a technology that will 
irreparably harm the environment or the socio-economic situation left 
for future generations. This equity also requires, however, that the present 
generation not deny future generations the possibility of benefiting from 
biotechnology and its socio-economic gains. Intragenerational equity 
dictates that biotechnology should be employed to improve the ability of 
members of the current generation to access resources and reduce poverty 
and not exacerbate existing inequalities. Biosafety decision making must 
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incorporate socio-economic aspects for these assessments to be made.64 The 
right to development must be implemented to meet developmental and 
environmental needs of present and future generations sustainably and 
equitably. This includes cooperating to eradicate poverty, in accordance 
with Chapter IX on International Economic and Social Co-operation of the 
Charter of the United Nations and the Rio Declaration on Environment 
and Development, as well as the duty to cooperate for global sustainable 
development and attaining equity in growth opportunities for developed 
and developing countries.65 All States in a position to do so have a further 
responsibility, as recognised by the Charter of the United Nations and the 
Millennium Declaration of the United Nations, to assist States in achieving 
conditions of socio-economic equity, and to ensure, at minimum, the 
eradication of poverty.66
Principle of Common but Differentiated Responsibilities
States and other relevant actors have common but differentiated 
responsibilities and are bound to cooperate in the achievement of global 
sustainable development and protection of the environment.  The principle 
applies not only to environmental protection but also to development 
of social goals.67 International  organisations, corporations (including in 
particular transnational corporations), NGOs, and the rest of civil society 
should cooperate with and contribute to this global partnership. Corporations 
have also responsibilities pursuant to the polluter-pays principle.68
Differentiation of responsibilities, although based mostly on the 
contribution that a State has made to the emergence of environmental 
problems, must also consider the economic and developmental situation of 
the State.69 Notably, the special needs and interests of developing countries 
and of countries with economies in transition, with particular regard to least 
developed countries (LDCs) and those affected adversely by environmental, 
social, and developmental considerations, should be recognised.70  From a 
sustainable development law perspective, biosafety decision making that 
permits socio-economic considerations may allow States to meet their 
common responsibility to ensure that there is adequate protection for the 
safe transfer, handling, and use of LMOs while providing a method for 
their economic and developmental situation. Ultimately, the principle 
suggests that the concept of common but differentiated responsibilities 
can be used to interpret and strengthen other corresponding principles of 
sustainable development law in situations of overlap or conflict between 
social, economic, and environmental regimes.71
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The Precautionary Approach to Human Health, Natural Resources, and 
Ecosystems
Article 26 allows Parties to consider socio-economic considerations when 
deciding on importing an LMO when the impact of the LMO on the 
conservation and sustainable use of biodiversity is concerned. In turn, both 
the AIA and LMO-FFP decision-making procedures allow precautionary 
decision making in light of insufficient scientific evidence on the extent of 
the potential adverse effects of an LMO on the conservation and sustainable 
use of biodiversity. Given the uncertainty over the socio-economic impacts 
of LMOs and how these could affect biodiversity, the ambit of the allowable 
precautionary decision-making in Articles 10(6) and 11(8) seems that it 
include  socio-economic factors, at least to the extent that these can be 
considered “relevant scientific information and knowledge.” Of course, 
States are also free to include socio-economic considerations in determining 
whether to make a precautionary decision under their own decision-making 
processes outside the Protocol as long as this does not conflict with their 
other international obligations.
Public Participation and Access to Information and Justice
There are three dimensions to this principle. First, individual people should 
have the opportunity to participate in official decision-making processes 
and activities that affect and impact their lives and well-being directly.72 
Second, to participate effectively, the public must have access to adequate 
information concerning  the issues, decision making, and policy making 
in which they are able to participate.73
Finally, when people’s rights have been infringed or when they have 
suffered harm, they should have access to administrative or judicial 
processes to challenge the measure and claim compensation.74
Numerous aspects of socio-economic considerations in biosafety 
decision making relate to these three dimensions. The first dimension 
suggests that public participation should be a common component in 
all biosafety regulatory regimes, because these regimes relate to socio-
economic development. In other words, because biosafety decision making 
can directly affect people’s lives and their well-being, these same people 
should have an opportunity to participate in the decision-making process. 
Indeed, the Protocol requires public consultation in decision making as well 
as public participation on the safe transfer, handling, and use of LMOs in 
relation to the conservation and sustainable use of biologic diversity, also 
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considering risks to human health. These are quite broad requirements that 
can be fulfilled in several ways.
The second dimension on public access to information is also reflected 
in Article 23 of the Protocol. This article requires that parties “[e]ndeavour 
to ensure that public awareness and education encompasses access to 
information on living modified organisms identified in accordance with 
the Protocol that may be imported.” Much of the literature also recognises 
that consumers want labelling of genetically modified foods or at least 
want to be able to find out what is in the food they consume.  Consumers’ 
reasons for wanting to know may well be based on socio-economic factors 
(for example, not wanting to consume something they feel runs counter 
to their philosophical values) rather than on environmental or health 
concerns. Biosafety regulatory regimes that are intended to support 
sustainable development need to consider how to fulfil the requirement 
of public access to information.
The final dimension is access to justice for people who think that 
their rights have been violated. Access to justice is necessary in cases 
of biosafety wrongdoing that harms socio-economic rights. This could 
include the ability to be compensated for damages when there has been 
a socio-economic biosafety injury (for example, lost profits by organic 
farmers whose crops no longer command a premium because they contain 
introduced DNA).
Principle of Good Governance
The importance of the principle of good governance in the inclusion 
of socio-economic considerations in biosafety decision making hinges 
primarily on its relationship with other principles of sustainable 
development law. The characteristics of good governance reinforce these 
other principles. Biosafety regulatory regimes that incorporate these 
principles result in systems that respond to the concerns of individual 
people and help to build consensus by acknowledging and not excluding 
the socio-economic elements of biotechnology and biosafety. In turn, 
this encourages participation in the biosafety process rather than creating 
disillusionment and disenfranchisement. Ultimately, it can lead to national 
visions of biosafety that incorporate and reflect the ideas of all. Perhaps most 
important, building biosafety regulatory regimes around these principles of 
good governance helps to create regimes that integrate the other principles 
of international sustainable development law.
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Conclusion
To varying degrees, many countries already consider socio-economic 
factors within their biosafety regimes and recognise that socio-economic 
considerations can be an important part of biosafety decision making. 
Although socio-economic assessment of new and emerging technologies, 
including LMOs, is an invaluable tool supporting decision making, 
it can present a difficult hurdle  if the assessment procedure  is not 
clearly defined.75 The  main  concern  is to determine  at which stage of 
the regulatory process inclusion is most useful, while maximising the 
functionality of the biosafety system.76 The  lack of a clear mechanism  for 
the incorporation  of socio-economic information into the process and the 
limited institutional capacity for socio-economic analysis in many countries 
are key barriers to the broader use of socio-economic considerations in 
biosafety decision making.
Socio-economic considerations in biosafety target values that states have 
already acknowledged as relevant and important. Numerous human rights 
treaties proclaim the rights of individual people to adequate food, work, and 
health. Nascent human rights to the environment are also emerging. These 
are just a few of the rights that could be affected by the socio-economic 
impacts of the products and processes of biotechnology. States that are party 
to the different treaties in which these rights are enunciated are bound to 
uphold these rights. In the realm of trade, members of the WTO are bound 
by the terms of the Sanitary and Phytosanitary Agreement (SPS) Agreement, 
which lists relevant economic factors that members must consider in their 
risk assessments and determination  of the appropriate level for sanitary 
or phytosanitary measures. These include the potential damage in terms 
of loss of production  or sales, the costs of control or eradication, and the 
relative cost- effectiveness of alternative approaches.77
Given that the socio-economic capacities, priorities, and processes 
of one region or area might not be identical to those of other regions, 
further analysis of biosafety decision making in different parts of the world 
is needed.78  The elements of socio-economic considerations relevant to 
biosafety decision making remain to be clearly defined, and an expert 
committee might be necessary to identify appropriate methods. Case 
studies and examples of different methods for assessing socio-economic 
issues and  their  strengths and  weaknesses should  also be  undertaken  to 
guide practitioners.79  The  development  of an institutional framework for 
the incorporation of socio-economic considerations in biosafety decision 
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making needs to be undertaken by first determining which institutions 
are most competent to address the issues. Methods should be identified 
and developed for use in the decision-making process, as well as methods 
for how to obtain stakeholder input during that process. Examples of 
decision-making frameworks and institutions that have been successful 
in incorporating socio-economic considerations also should be identified 
and described.80
From a sustainable development law perspective, the consideration 
of socio-economic information as a part of the biosafety decision-making 
process brings the field of biosafety closer to the goal of sustainable 
development through the integrated consideration of economic and social 
development, and environmental protection. Obtaining information and 
knowledge on socio-economic issues further supports biosafety regulatory 
regimes that can contribute to sustainable development and demonstrate 
how to build synergies between economic, environmental, and social law.
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Introduction   
The process of developing and implementing biosafety systems across 
Africa is not a straightforward exercise. This reality is acknowledged by 
stakeholders on the continent, and those outside who are making efforts 
to assist African countries achieve this objective. Finding of the best way to 
untangle the complexities and forces around the desired policy outcomes 
faces many realities, some of which have both positive and negative 
impacts on the processes depending on how they are framed or managed 
by contending actors. This article reflects on policy-making processes 
in agricultural biotechnology in Africa especially, Sub-Saharan Africa 
(SSA), examining how interdependencies and differences of interests and 
72     Asian Biotechnology and Development Review
aspirations among stakeholders at cross-national, national and institutional 
levels coalesce to inform, facilitate or constrain policy processes. This article 
is based on observations and reflections of the NEPAD Agency African 
Biosafety Network of Expertise (ABNE) which was established in 2008 
to build functional biosafety systems in Africa. The aim of this article is 
to explore and discuss the relationships that emerge between regulators, 
public and private developers of the technology, intermediaries, as well as 
the lay public and how these may best be managed for the benefit of the 
policy processes. 
Participation of multiple stakeholders in decision making processes is 
important, yet in most cases a lot still needs to be done beyond participation, 
to ensure that the representation of stakeholder concerns also influences the 
outcome of decision making processes, and importantly helps in alleviating 
the socio-economic challenges that the continent faces perennially. The 
ABNE was established to provide a broad-based platform for context-driven 
formulation and implementation of biosafety systems across Africa. 
Biotechnology
Biotechnology is a pervasive technology, which brings together interests 
from many sectors including research and development, product 
development, manufacturing, commercialisation and downstream 
delivery. Management of this technology at the policy and regulatory 
levels is, therefore, inherently multi-level and multi-actor, and this brings 
both challenges and opportunities for policy actors. In the Sub-Saharan 
Africa region, there have been many efforts since the early 2000s towards 
developing and implementing systems for managing biotechnology. 
There are many individual, institutional, sectoral, national, regional and 
international players in these efforts and their multiplicity and varying 
levels of involvement in the issue in space and time brings many dynamics 
to these efforts for developing countries.
Role of technology 
It is recognised that new technologies can play an important role in 
addressing food security challenges the world over, including Sub-Saharan 
Africa (FAO 2004). However, efforts to effectively access and exploit 
technological knowledge are at the mercy of various context specific 
economic, political, social and cultural realities. In SSA countries, where 
the vast majority of the population relies on farming for their livelihood, 
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it is important to consider the impact of policy making processes on 
food security and the socio-economic status of poor farmers (Mugwagwa 
et al. 2010). 
The mechanisms that are developed for technology governance 
reflect a myriad of complex realities. Regulations as instruments of 
technology governance provide the norms and standards for quality, safety, 
effectiveness, environmental protection, intellectual property protection, 
among others. With regard to modern biotechnology in agriculture, 
developing countries recognise the importance of effective regulatory 
systems (Persley 1999). The ways in which biotechnology is governed 
not only determine its ability to achieve socially desired aims, but also 
give important signals about the direction of technology development 
(Cohen and Paarlberg 2004). The two elements are linked insofar as the 
credibility and legitimacy of new technologies, which to some extent may 
be strengthened by incorporating public consensus in policy processes, are 
important in facilitating technology use and development (Jaffe 2004). 
In Sub-Saharan Africa, like elsewhere in the developing world, the quest 
for new technologies and new ways of working together across disciplines, 
sectors, countries and regions is now widely seen not as an option but an 
imperative in the pursuit of socio-economic stability. There is a new and 
rising reality that new and old problems alike have become increasingly 
pervasive, defying disciplinary, sectoral, national or regional boundaries. 
Within these arenas exist opportunities and solutions to the problems, 
and as well avenues for magnification of the problems (Mugwagwa 2010). 
Challenges have increasingly become unusual in their magnitude, in the 
way they spread and in the way they combine with others to present even 
bigger challenges. Innovation is seen as a way of breaking new ground, 
breaking barriers and doing business away from the beaten path, and 
ensuring that effective technologies, products and services do indeed reach 
the millions of people who need them. With respect to addressing food 
security challenges, the role that new technologies can play are widely 
recognised the world over, including Sub-Saharan Africa (SSA) (FAO 2004; 
UNCTAD, 2010). It is also widely acknowledged that a nation’s ability to 
create, acquire, accumulate, diffuse and utilise scientific and technological 
know-how and knowledge is a major determinant of its capacity for the 
industrial and socio-economic development needed to improve people’s 
livelihoods. Differences in the acquisition, accumulation, diffusion 
and utilisation of science, technology and innovation go a long way in 
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explaining the income disparities between rich and poor countries (Juma 
and Serageldin 2007). Admittedly, efforts to effectively access and exploit 
technological knowledge face various context specific economic, political, 
social and cultural realities. 
In SSA, a myriad of efforts have been made at various levels to 
harness and deploy technologies to reign in food insecurity and other 
socio-economic challenges bedevilling most of Africa. For example, 
biotechnology, viewed as a continuum of both traditional and modern 
biological techniques, is one of the technologies which has been at the 
centre of many efforts and is largely seen to (yet) have a significant role 
to play in mitigating some of the challenges and leapfrogging Africa to 
higher levels of development and self-sufficiency. A number of challenges 
confront these efforts, among them being the lack of effective innovation 
systems (UNCTAD 2010). Focusing specifically on how to reverse declining 
agricultural productivity, UNCTAD, the Consolidated African Agricultural 
Development Plan (CAADP) and a number of other organisations and 
frameworks all point to the need for creation and employment of 
‘agricultural innovation systems’, which would provide an ‘enabling 
framework’ not only for adoption of existing technologies, but also the 
development of new ones suited for African needs.
What is an Enabling Framework and What Does It Do?
Creating an enabling environment is a critical step in the quest to harness 
and deploy technologies (Chataway et al. 2006; Juma and Serageldin 
2007). In Technology and Innovation Report 2010, UNCTAD defines an 
enabling environment for technology and innovation in agriculture as ‘one 
that provides the actors, skills, institutions and organisations required to 
promote the use, dissemination, diffusion and creation of knowledge into 
useful processes, products and services’ (UNCTAD 2010: xiii). The ability 
of the agricultural innovation system to be able to access, use and diffuse 
knowledge embedded in agricultural technologies depends on the presence 
of an enabling framework that supports the emergence of technological 
capabilities by strengthening existing linkages, promoting new linkages and 
fostering inter-organisational learning that leads to capital accumulation 
and technical change. Such an enabling environment, by definition, is one 
that strengthens the absorptive capacity of local actors while protecting 
their interests through a policy framework that recognises their legal 
rights and privileges, linkages, socio-cultural norms and historical context 
(UNCTAD 2010: xiii).
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Among many motivations, this article stems from a desire to contribute 
to understandings of the context-specific differences and similarities 
embedded in or transcending processes to establish and employ 
biosafety systems as an enabling tool for harnessing the benefits of 
modern biotechnology while minimising the risks posed by the same. 
This technology is seen as one key ingredient in the toolkit of solutions 
for addressing food insecurity and broader livelihood challenges in 
developing countries.
Knowledge and Power Key in Policy Processes 
One of our key observations at ABNE is that knowledge and power are 
central elements in policymaking processes in Africa. Biotechnology is 
knowledge intensive and problems around it, including social ones, are 
generally couched in scientific terms. Nevertheless, scientific considerations 
and political power are intertwined in decision making processes. Shore and 
Wright (1995) highlight, “Policies are most obviously political phenomena… 
‘political technologies advance by taking what is essentially a political problem, 
removing it from the realm of political discourse, and recasting it in the neutral 
language of science’.1 Central to this process is the use of ‘expert’ knowledge in 
the design of institutional procedures.” The relationships that are dominant 
in framing regulations are based on a dynamic and complex interplay 
between knowledge and power. 
Scientific evidence plays a dominant role in the decision making 
process of biotechnology. However, contrary to some assertions, ‘experts 
in science’ do not necessarily override in all instances of policymaking. 
The uncertainty surrounding biotechnology provides a possibility to 
supersede ‘scientific evidence’ and apply the precautionary principle. “The 
precautionary principle is not a natural scientific concept but a policy principle 
which is meant to illuminate the credibility of the idea of anticipatory policy and 
to create new coalitions. In that context the precautionary principle holds that 
policymakers will sometimes have to decide on action even if there is no scientific 
evidence of a causal link” (Hajer 1995:67). This leaves open the possibility 
that if science is not leading to a decision that is favourable to the national 
socio-economic good, decision-makers can disregard it on the basis of the 
uncertainty on potential risks and evoke the precautionary principle.2
The processes through which regulatory systems emerge are driven 
by complex forms of interactions amongst actors. To a large extent, the 
interactions are underpinned by the nature of knowledge for which the 
regulatory mechanisms are developed as well as the power dispersal, which 
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influences the orientation of the regulations (Francis 1993). The knowledge 
intensive nature of biotechnology and the high uncertainty surrounding 
possible human and environmental risks tends to overwhelmingly favour 
scientific and technical (such as legal professions’) expertise in decision 
making processes. Other actors that may have a relatively strong influence 
in shaping biotechnology regulations are private investors, although, their 
influence closely depends on the government’s position with regard to its 
strategic economic priorities.  
Long Tradition of Mediating Multiple Stakeholder Interests
The establishment and implementation of the ABNE follows an age-old 
African tradition of creating and implementing framework for coordinating 
scientific efforts. Documents efforts emerged as far back as the late 1920s 
and led to the African Survey in 1936 (Gruhn 1971). The organisations that 
emerged out of these efforts primarily aimed at establishing a common 
communications network that could enhance utilisation of African 
resources. 3 What has also emerged over the years and as observed in the 
biotechnology and biosafety terrain is a shift from top down, exclusive 
approaches - which have received incessant criticism in recent times to 
a bottom-up approaches. However, the bottom-up approach may not be 
clearly evident in all biotechnology decision making processes in SSA, 
with some organisations being labelled as techno-savvy ‘champions’ of the 
technology. Invariably these ‘champions’ are a direct product of the pre-
existing structure (top down model); they generally have a history within 
public research institutes, but have been ‘entrusted’ with representing the 
concerns of the poor in biotechnology decision making process, not in the 
least because of their apparent advisory independence. They are thought 
to have strong links with the poor and, therefore, well imbued with their 
concerns and at the same time to be in a strong position for independently 
articulating the socio-ethical concerns in the highly scientific problem 
framing contexts of biotechnology policy. 
The ‘champions’ operate within networks and are seen to play an 
important role of mobilising and engaging a wide range of actors whose 
views are then represented in policymaking processes. While the extent to 
which such activities revolve around knowledge exchange rather than on 
persuasion is a matter of debate, our perceptions is that various forms of 
cumulative and path dependent learning are occurring within this linear 
model, on account of its ability to recreate itself, and capacity to persist. 
Importantly, it is crucial within these interactions, meaningful reflexivity 
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with some potential for institutional change to reflect the needs of poor 
consumers and farmers should take place. The diversity of sites and the 
types of knowledge that contribute to decision making processes ought to be 
expanded and sustained. The ABNE has implemented a number of activities 
to this end in collaboration with other partners in the biosafety arena.
Recognition of Core Competencies is Key
Agricultural biotechnology is a knowledge intensive form of modern 
technology. It requires a strong scientific knowledge base of core 
competencies. This can facilitate adequate assessment of potential risks 
and benefits as well as provide sufficient flexibility for incorporating the 
emerging scientific evidence and shifting boundaries of social and ethical 
debates that raise fresh challenges to the credibility of biotechnology. Our 
experience at the ABNE confirms that suitable scientific and technical 
competences in risk assessment are limited in many SSA countries. This 
is further compounded by the fact that other forms of competencies for 
articulating socio-ethical concerns also tend to be scarce in SSA. For example, 
competencies for information communication and management, which 
are critical in developing an official and effective information strategy 
aimed at providing actors with sufficient transparency to allow for better 
articulation of specific interests, are limited in most countries, necessitating 
the need for partnerships and synergies among different interest group. An 
adequate information strategy has multiple roles including not only for 
educating the public and countering ‘extremist’ views, but also for gauging 
public attitudes, which are important in guiding institutional changes that 
are necessary in facilitating biotechnology innovation strategies as well as 
policy development and implementation (Levidow 2007).
There are constant fears that the scenario in SSA could imply that 
those with scientific and technical competencies (though limited) drive 
decision making processes based on the deficit model of knowledge 
production (Kingiri 2010). SSA countries for the most part rely on bilateral 
and international assistance as well as multinational companies to develop 
scientific and technical competencies and formulate regulatory frameworks 
(Cohen and Paarlberg 2004). As such it is not sufficient to only recognise 
that biotechnology is important in the development process in Africa. 
The challenge lies in identifying and implementing interventions that 
adequately take technological capability building into account (important 
within the context of early development stages of SSA economies), and 
provide robust solutions to the pressing social challenges. Related to this 
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is the importance of understanding that the existing perceptions on the 
role of scientific capabilities do indeed have potential to shape the existing 
decision making processes in agricultural biotechnology. The NEPAD 
Agency’s co-evolution approach operationalised through the African 
Biosciences Initiative (ABI) and the ABNE aims to address both the scientific 
capacity challenges and perceptions on regulatory trajectories (Juma and 
Serageldin 2007)
Scoones (2002b:116) notes that a key assumption of pro-poor 
agricultural biotechnology advocates is that “regulatory issues will be dealt 
with throughout the world by international ‘capacity building’ efforts 
in developing standardised, harmonised regulations for the agricultural 
biotechnology sector. With new regulations in place these will be enforced 
consistently and effectively throughout the developing world.” Such efforts 
of capacity building and harmonisation of regulation may provide simple 
and standardised regulatory procedures that encourage investment in the 
biotechnology industry may facilitate trade, but may not substantially 
promote the achievement of context specific moral imperatives. There 
are numerous aspects that limit the ability to effectively incorporate the 
concerns of the poor in biotechnology regulatory frameworks (Newell 
2002; Glover 2003).  
The ‘science-based approach’ to problem framing is intricately and 
determinately tied to the knowledge intensive nature of biotechnology and 
appears to be core in determining the extent to which a range of objectives 
are achieved. Attempts to incorporate the concerns of poor farmers and 
consumers in SSA are generally undertaken by ‘champions’ who mainly 
operate within non-governmental organisations (NGOs). NGOs are, 
therefore, thought to have strong links with the poor and are at the same 
time in a better position to articulate their socio-ethical concerns in the 
highly scientific problem framing contexts of biotechnology regulation. 
Rayner (2003:165) points out that: “NGOs tend to explain their motives 
for supporting public participation in terms of extending democratic 
control”. However, in SSA ‘champions’ (or the NGOs within which the 
‘champions’ operate) who wield the strongest influence on decision making 
processes cannot be assumed to hold interests that are entirely compatible 
with extending democratic control to the public (Harsh, 2009:231). The 
formulation of a regulatory framework is further complicated by the 
continuously changing regulatory environment and, therefore, offers no 
standard approach of reflecting the heterogeneity of the complex contextual 
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realities. This raises critical questions in terms of incorporating context 
specific realities of SSA such as the challenge of food insecurity and the 
socio-economic status of poor farmers. 
While it is obvious that issues of safety and environment dominate 
the ways in which the biotechnology innovation trajectory is evolving in 
SSA,4 it is difficult to argue that these aspects dominate the public debates 
that relate to policy making processes at the local level. Contestations of 
biotechnology are closely tied to the apprehension that stems from the 
power imbalance in externally triggered processes.
There are clear though perhaps not sufficient attempts to define 
risk more broadly and include the relationship between biotechnology 
innovation and food security. Nevertheless, this does not interrogate the 
ability of ‘sound science’ to tackle the broader socio-economic challenges 
of the poor. Furthermore, ‘sound science’ is in some cases viewed as a 
magnet for pursuing the harmonisation of regulatory systems in the region. 
Numerous discussions about the importance of pooling resources in the 
region encourage countries without sufficient scientific and technical 
capabilities as well as funds to engage in harmonisation processes because 
missing such opportunities is viewed as a risk in its own right (Mugwagwa 
2010). It is also not uncommon for SSA countries to borrow key elements 
of bio-policy from the few that already have one without necessarily 
questioning core defining elements of innovation trajectories. Wafula 
and Clark (2005) report that: “Uganda was open in terms of borrowing 
key elements and tenets of a biotechnology policy from countries such as 
Kenya, Zimbabwe, South Africa, Namibia and the European Union.”
The biotechnology discourse is enshrined in ‘champions’ whose 
framings of the connection between biotechnology innovation and food 
insecurity are shaped by perspectives that are contradictory and fragmented. 
Zambia is perhaps an exception as was demonstrated by the 2002-2003 food 
crisis. It is noted that the decision making process on whether to accept 
GM food prominently featured the Zambian scientific community that was 
able to focus ‘not only on purely scientific evidence, but also on the potential 
political and economic impacts of allowing GM food aid into the country’, (Clark 
et al. 2007).5 Nevertheless, Glover (2003) notes that: “In countries which 
lack the capacity to compete in biotechnology, or where the degree of 
vested interests or the intensity of controversy is low, it is more likely that 
participation will be feasible and that public concerns will be allowed to 
frame the issues under consideration, as well as shape the decisions to be 
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made.” On the whole, however, narrow perspectives of biotechnology in 
most SSA continue to have a disproportionate role in influencing policy. 
‘Sound science’ determinately guides the formulation of biotechnology 
regulation and innovation in SSA. While this is not a peculiarity of SSA 
countries, the emergence of ‘champions’ influences the relationships in 
decision making processes in specific ways. For example, the existence of 
‘champions’ takes the public one step away from questioning the extent to 
which science on its own can adequately take into account the challenge 
of food insecurity and the socio-economic status of poor farmers. 
It would be disingenuous to suggest that the ‘divinity’ attached to 
science is unshakable in SSA, particularly owing to the rapid changes 
that are occurring in the wider spectrum, for example, with regard to 
information and communication technologies. Nevertheless, public 
participation remains encapsulated in ‘champions’ and is largely about 
persuasion rather than consultation, (Harsh 2009). The adherence of 
‘champions’ to a knowledge (biotechnology) elite community gives them 
considerable influence in decision making processes, particularly owing to 
the uncertainty that surrounds biotechnology (Keeley and Scoones 2003). 
It is difficult to argue that in SSA the biotechnology debate in decision 
making processes is evolving towards the more mature debates in the 
north. That notwithstanding, decision making processes are intrinsically 
‘evolutionary’, and the existence or absence of opportunities for 
effective public participation in one period does not preclude variations 
in the future.
Implications for Food Insecurity and the Concerns of Poor Farmers
The inclusion of public participation in biotechnology decision making 
processes is important and will continue to be seen as necessary, although 
it is difficult to argue that it has had a positive and significant impact in 
aligning biotechnology innovation to social needs in SSA. In some countries, 
decisions about biotechnology innovation trajectories have largely been 
driven by external efforts such as international research institutes, donors 
and non-governmental organisations and public participation has been 
facilitated informally though public-private partnerships. The role of 
the government has been in some cases mainly reactive and its ability 
to guide biotechnology innovation, let alone align it to local needs, has 
been minimal (Harsh 2005).  It is, nevertheless, important to emphasise 
that public participation is not the panacea for addressing the needs and 
ecological environments of poor farmers and consumers. 
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The ability to adequately factor practical problem-solving mechanisms 
for socio-economic issues into innovation processes requires a systems 
approach to innovation (Hall 2005). Even within such a holistic approach 
public participation though important cannot serve as a ‘silver bullet’ to 
agricultural constraints. One of the shortcomings of the systems approach 
in its application to SSA relates to the central question of demand and 
innovation. Whilst demand dynamics are viewed as critical in stimulating 
and defining technology paths that are congruent to the consumer and may 
perhaps better reflect the preferences and concerns of the public, SSA does 
not provide a very strong case in support of this argument in agricultural 
biotechnology. As mentioned previously, intermediary consumers of 
biotechnology, particularly private investors in the biotechnology industry 
(that for the most part target secondary markets) play a critical role in 
stimulating demand and orienting the innovation trajectory. 
In the case of industrialised countries it may be argued that: “[O]ur 
consumption decisions are likely to have a greater impact in shaping our lives 
than our ballots. Thus, popular choices about governance seem to be increasingly 
made in the marketplace rather than in the legislature”, (Rayner 2003). Neither 
ballots nor consumption decisions in SSA seem to offer much in terms of 
shaping governance. However, a systemic approach provides a premise 
for addressing the shortcoming of agriculture in a more integrated way 
by identifying gaps and providing solutions from a holistic perspective. 
Other strands of literature such as the value chain analysis also provide 
avenues to identify broader and complementary channels for responding 
to the concerns of poor farmers and consumers in SSA (Kaplinsky 2005).
Conclusion
This article has sought to illuminate the nature of relationships that exist in 
policy processes in SSA. It demonstrated that effective public participation 
or more specifically the adequate representation of the socio-economic 
realities facing poor farmers and consumers in biotechnology decision 
making processes, despite its importance, is often not given consistent and 
effective attention. However, the existence or absence of opportunities for 
effective public participation in one period does not preclude variations 
in the future. Decision making is a continuous process, which involves 
iterating negotiations that evolve with changing needs in a path dependent 
way and are principally based on continuous learning. Nonetheless, while 
it is not expected that improved representation would on its own be 
sufficient in addressing the challenge of food insecurity and the plight of 
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poor farmers in SSA, it can make an important contribution to attempts for 
aligning biotechnology to the socio-economic welfare of the poor. Equally 
important is the importance of managing differences and dependencies 
amongst different actors within the arena. 
Endnotes
1 Quoted from Dreyfus and Rabinow (1982:196) by Shore and Wright (1997)
2 See the case of Zambia’s refusal to accept milled GM maize during the 2002-2003 food 
crisis. (Clark et al. 2007)
3 These efforts led to the creation of the Scientific Council for Africa South of the Sahara 
(CSA) in 1949, and the Commission for Technical Co-operation in Africa and Scientific 
Council for Africa South of the Sahara (CCTA) in 1950.
4 For example, in Ethiopia which has wide ecological diversity and rich biological resources, 
the leading authority in the formulation of a biosafety policy is reported to have adopted 
precautionary principles that limit the use and development of biotechnology; it weakens 
the purported argument of focusing on small farmers and seems strongly guided by concerns 
of biopiracy (Ayele 2007). In a different scenario, it has been suggested that SSA serves 
as a battle ground for EU-US disagreements on GM trade. The US aggressive approach 
confronts the EU cautious approach to GM crops by expanding biotechnologies in SSA - a 
source of EU agricultural products - and in so doing seeks to encourage the EU to develop 
more accommodating biotechnology policies (Clark et al. 2007:101). The financial resources 
accruing to SSA from such disagreements cannot be overlooked as an important element 
drives local debates.
5 This may have been and perhaps paradoxically facilitated by the absence of a vibrant 
biotechnology industry. 
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Understanding the Need for Socio-economic Considerations 
In the negotiations for United Nations Protocol on Biosafety, a coalition 
of representatives of the Third World countries, civil society organisations, 
etc., advocated for strongly worded socio-economic regulation of 
biotechnology. After protracted negotiating this resulted in the Article 
26 of the Cartagena Protocol on Biosafety (CPB), which deals with Socio-
economic considerations (Kinchy et al. 2008).  At the global level, as there is 
no other convention to deal with Socio-economic Considerations (SECs) in 
biotechnology regulation, the CPB has emerged as the central convention 
that permits taking into account both biosafety considerations and SECs 
arising from the impact of LMOs on the conservation and sustainable 
use of biological diversity. CPB being a Convention negotiated under 
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Convention on Biological Diversity (CBD) the emphasis on conservation 
and use of biodiversity is understandable. 
Though the CPB came into force in 2003, socio-economic aspects have 
not been given much importance in terms of implementing Article 26 in 
letter and spirit. Only 56 per cent of the National Biosafety Frameworks 
mentions SECs.1 However, the mere mention of SECs does not guarantee 
that they have been fully incorporated in the framework. Often regulations 
of different countries reveal lack of clarity on SECs, while methodological 
issues create a problem in implementation since there is no clarity on that 
(Chaturvedi et al. 2012).  
Moreover, socio-economic impacts of GMO market approvals are 
considered in a broad range of countries including Armenia, Bangladesh, 
Bhutan, Cambodia, China, Honduras, India, Lebanon, Mauritius, Nigeria, 
the Philippines, South Korea, and the Syrian Arab Republic. However, 
the scope and nature of requirements seem to vary considerably between 
these countries as does the way they are being established in the part of 
national legislation, draft legislation, policies or regulatory practice. On 
the other hand the USA, Canada, Japan, and Thailand are examples of 
countries which have not taken into account SECs. Among the EU/EEA 
Member States, only France and Norway are known to explicitly assess 
socioe-conomic impacts; the Austrian national law on GMOs includes a 
provision on socioeconomics which has not yet been implemented though 
(Spok 2010). Although socio-economic considerations are included in 
the biosafety frameworks of a number of countries worldwide, regulatory 
experience seems to be limited (Zepeda 2009; Anita et al. 2011). Although 
Article 26 is concerned with SECs the need for including SECs in decision 
making has to be understood in a broader context.  Article 26 thus can be 
a guiding article and Parties are at liberty to go beyond the requirements 
under Article 26 in taking SECs into account in decision-making. 
Socio-economic considerations is a broad term although the focus of its 
usage in Article 26 is specific. Taking into account Socio-economic Impacts 
and Environmental Impacts of technologies is part of policy making and 
Technology Assessment exercises take into account broader implications 
and impacts of a given technology. Similarly, methods like Constructive 
Technology Assessment (CTA) try to integrate the expectations from the 
technology into technology assessment so that the scope for directing 
technological change is explored. Similarly, the Environmental Impact 
Assessment has been part of decision making and it is mandatory under 
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various laws to protect the environment and to control pollution. In case 
of agricultural technologies there is enough literature on impacts of Green 
Revolution on employment, on different classes of farmers, on women and 
in general on the socio-economic impacts of Green Revolution. But most of 
these studies have been done after introduction of Green Revolution and 
these studies have helped in assessing the impacts of Green Revolution and 
to take suitable steps to minimise the negative impacts of Green Revolution. 
For example, studies indicated that the introduction of mechanised farming 
during the Green Revolution increased the inequity between small-scale and 
large-scale farm communities (Conway 2003) and reduced the availability 
of agricultural jobs performed by women (Paris 1998). 
In recent years, the idea of Anticipatory Governance of technology has 
been put forth as another mechanism and this goes beyond Technology 
Assessment as the idea is that governance of technologies is needed at 
different levels. Governance is a broader term than regulation and part 
of the Governance process includes dynamic assessment of impacts of 
technology and anticipating the potential impacts taking into account 
the trends and trajectories in technology. In case of nanotechnology and 
synthetic biology and technological convergence, these new ideas are being 
debated while CTA is being practiced in Europe. 
Technologies never operate outside a biophysical and social context, 
and it is their interaction with their contexts that generates effects, impacts 
and implications. In order to identify and evaluate the potential harms and 
benefits of a technology, we must know how it is likely to interact with its 
context, which requires knowledge of specific contexts as much as it requires 
knowledge of the technology itself.  However, in case of technologies that 
have a wider and long-term impact assessing their impacts is not easy 
because it is difficult to assess accurately all the impacts of a technology. 
Moreover, the diffusion and use of technology is also affected by the impacts 
of the technology resulting in unanticipated developments and impacts. 
In case of LMOs, their impacts need not be confined to agriculture and 
food production and environment (Pavone et al. 2011). The Agenda 21 
recognising this suggests:
“Like with most new technologies, research in biotechnology 
and the application of its findings could have significant positive and 
negative socio-economic as well as cultural impacts. These impacts 
should be carefully identified in the earliest phases of the development 
of biotechnology in order to enable appropriate management of the 
consequences of transferring biotechnology.”2 
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Nationally and internationally risk perceptions about LMOs (i.e. 
GMOs) have a role in public’s acceptance or rejection of GMOs, 
particularly in agriculture and food. It is obvious that understanding 
public perceptions of risk related to LMOs depend critically on 
understanding the socio-cultural factors involved (Finucane 2002). For 
LMOs in agriculture and genetic engineering an important question is 
whether genetic engineering is compatible with nature, that is, are they 
safe enough to be used without damaging nature (Ramjoue 2008). Here 
also perceptions of risk matter and risk assessment is done to assess the 
consequences of introducing LMOs in natural environment including 
the long-term impacts on biodiversity. 
Issues in Defining SEC 
There is no clear definition as to which aspects can clearly be defined as 
falling within the scope of SECs. Basically every possible effect that does 
not clearly constitute a direct environmental or health effect could be 
considered as SEC (for example, any direct or indirect effect linked to LMOs 
becoming manifest in society). Consequently, the meaning and use of the 
term varies in the literature. Often the focus is on economic and/or social 
factors, but sometimes ethical issues are also included (Norwegian Gene 
technology Act 1993). While in India its biosafety system provides for 
evaluation of the economic benefits of LMOs through systematic evaluation 
of agronomic performance; under the Revised Guidelines for Research in 
Transgenic Plants and Guidelines for Toxicity and Allergenicity Evaluation 
of Transgenic Seeds, Plants and Plant Parts 1998, it has been specified that 
data should also be generated on economic advantage of the transgenic over 
the existing varieties. Though there is an environmental objective, most of 
the provisions have a direct bearing on agricultural production practices as 
also on the trade and commerce. India is now developing a comprehensive 
regulatory framework by establishing Biotechnology Regulatory Authority 
of India (BRAI) to regulate biotechnology (Chaturvedi et al. 2012).
Further, while discussing the scope of SECs it also needs to be considered 
that when a country includes SECs in the LMOs biosafety regulatory process 
it has to decide if the SECs should be voluntary or mandatory or if it should 
be carried out for approval (ex ante) and/or for post-release monitoring 
(ex post) and which methodology should be applied. For ex ante studies 
the choice of methods is limited and they necessarily will be based on 
projections and assumptions. 
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Comparison of current approaches to the inclusion of SECs in the 
GMO regulatory process in Argentina, Brazil and China shows significant 
differences. In Argentina, SECs are mandatory and comprise the ex ante 
assessment of economic impacts on trade and competitiveness. Brazil has 
introduced a non-mandatory SECs with an open scope and it is decided on 
a case-by-case basis if they are used. In China, the SECs are currently not 
included in the guidelines and regulations (Lusser et al. 2012).
Moreover since the overall scope for socio-economic assessment seems 
to be extremely broad, the question of the boundaries of a socio-economic 
assessment is highly pertinent. Baselines are needed to be defined for 
socio-economic assessment. It needs to be discussed which socio-economic 
impacts are considered acceptable, desirable or avoidable. It has been felt as 
a need that a definition of terms and indicators is needed and clarification 
on whether organic or conventional agriculture should be the baseline 
for comparisons. In addition, standards for data collection are needed 
(Anita et al. 2011).
Methodological Issues for SECs
In order to know which data is needed, some decisions need to be made 
regarding a few basic issues like the scope of the assessment, the spatial 
and temporal scale of the assessment, or appropriate criteria and indicators. 
Before discussing the status of the data which might be of relevance for 
a socio-economic assessment, some general issues, which need to be 
considered, are presented later in this article. While in an Environmental 
Risk Assessment (ERA) conducted for the authorisation of GMOs every 
single event is considered a case and subject to separate assessment, socio-
economic effects may rather depend on a specific GM crop species (e.g. 
soya bean) than on a specific event (e.g. MON89788). One view is that since 
socio-economic data is crop/trait/application-specific but not necessarily 
event-specific, that is, there is no need to produce extensive socio-economic 
data for each particular event. Supplementary event-specific information 
might only be relevant if important characteristics of the crop/trait/
application combination are being affected (Spok 2010). This is important 
if there is a stacking of traits in an event or a GMO which is being test. 
However, different countries adopt different norms in regulating them. 
The differences in regulation with APEC can be illustrated by regulation 
of stacked events. Within the APEC region Australia, the USA, Canada and 
New Zealand don’t require submission of additional data if the individual 
traits are already approved and if the combination is not to result in 
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concerns about safety while Japan treats them as individual or new events 
and thus separate approvals are needed. While the Philippines and Korea 
have devised regulation that eschews both the above approaches, Malaysia 
is yet to develop a policy on this. (Margarita Escaler et al. 2012)
On the other hand for LMOs socio-economic effects are very much 
linked to a certain type of LMO application. Some argue that the excessive 
cultivation of HR soya bean, accompanied by an increased use of herbicides, 
has far-reaching socio-economic consequences (for example, decrease of 
domestic food security, displacement of farming populations (Antoniou et 
al. 2010)). In addition, the outcome of an assessment may differ, depending 
on the level at which socio-economic effects are studied – either at the 
microeconomic (e.g. farm level) or at the macroeconomic level (e.g. national 
level). Therefore, socio-economic impacts and the generation of respective 
data on a specific crop or trait (e.g. herbicide tolerance) or a combination 
of these may be important.
The level at which socio-economic effects are studied is of utmost 
importance for the collection and evaluation of socio-economic data in 
general, and for the identification of adequate indicators in particular. 
Today most studies in developing countries are conducted at the farm or 
the household level, that is, the basis to which all collected data refer to. 
However, economic analysis can and should also be conducted for whole 
economic sectors, for example, the seed sector, food trade sector, the food 
processing industry, commodity trade, or it should be conducted at the 
level of political units (e.g. communities, regions, countries or federations). 
In addition, economic models may differ in their underlying assumptions 
of market situations, e.g. by including or excluding trade. When assessing 
socio-economic impacts on a certain level, the given environmental, 
economic and socio-cultural conditions in a country or region need to be 
considered. Conclusions derived from socio-economic assessments cannot 
easily be transferred to other countries or regions.3 Socio-economic impacts 
are also determined by societal circumstances. It is also important to define 
the data that need to be generated and the selection of the scientific methods 
that are to be applied (Anita et al. 2011).  
Another issue associated with this is the limitations of the availability 
of data. There are also scientific studies showing the limitations of data 
availability (e.g. Barbero et al. 2008; Smale et al. 2009 and Friends of the 
Earth 2010). Methodology for environmental and health risk assessments 
is well-developed and implemented in the regulatory process of GMOs, 
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whereas studies on the socio-economic impact of the cultivation are carried 
out mainly by academia. However, a recent review revealed that even 
academic research does not cover all relevant sectors equally (most of the 
studies focus on the farm level, with fewer studies on the other sectors such 
as seed, food, feed consumer and social impacts on a broader scale) and that 
methodology has to be developed  further (Lusser et al. 2012). Furthermore, 
studies on wider micro-economic effects (e.g. impacts on non-adopters, 
household income) are rare in particular for developing countries. Some 
studies are available on the macro-economic level. Thus it can be argued 
that comprehensive studies are needed but the methodological issues have 
to be addressed before undertaking them.
Moreover, there is a need to clarify the formation of normative baselines, 
key concepts, criteria, impact dimensions, endpoints and methods.   The 
degree of public participation might be flexible depending on the issues at 
stake. It is also important to consider the characteristics of socio-economic 
data and the differences compared to data from scientific risk assessment 
(Spok 2010). A number of methodological issues are associated with the 
impact assessment of GM crops at farm level, especially in developing 
countries where researchers collect data in personal interviews with farmers 
due to the lack of reliable sources and where random sampling may not 
be feasible. The most commonly applied methodologies have been partial 
budgets and econometric models of farm production, in which researchers 
tested hypotheses related to the yield advantages, labour and pesticide 
savings associated with adoption. Data quality has been a major limitation 
of early studies, where samples were typically small, field observation 
periods were brief, and estimates of key parameters were often based on 
farmers’ recall. 
Perhaps the most critical concern has been self-selection bias, that is, 
the fact that farmers adopting the GM technology may also be the most 
efficient, or those with greater endowments and better access to markets 
or information. Additionally, the decision to grow a GM crop may be 
endogenous, and explained by other factors which are unobservable 
or not integrated into the model (like the pest pressure for instance). 
Thus these methodological issues can be addressed by using advanced 
econometric techniques (Lusser et al. 2012). But in order to obtain more 
robust conclusions, multiple methods are needed. Furthermore, there is a 
lack of rigorous consideration of impacts on labour, health, environment, 
equity, poverty (Smale et al. 2008). Thus for assessments of broader socio-
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economic impacts or complex dimensions such as, multifunctionality of 
agriculture quantitative methods alone may not be sufficient and need to 
be combined with qualitative methods (Spok 2010).
In a recent article Glen Stone has pointed out that both supporters 
and opponents of Bt Cotton in India claim that their arguments are based 
on ‘facts’ and these ‘facts’ are repeatedly used to buttress their claims. He 
points the issues in constructing and interpreting these facts and argues 
that biases like self-selection have to be considered in understanding the 
claims based on these ‘facts’ and interpretation of the studies based on 
empirical field work. In the case of Bt Cotton an important and contested 
claim is that Bt Cotton has contributed significantly to the increase in the 
cotton output in India in 2002-2012. In 2002 Bt cotton was approved for 
commercial cultivation. (Stone 2012) 
Indicators for Measuring SECs
A methodological framework should be built up to define socio-economic 
indicators that have to be monitored and to establish appropriate rules 
for data collection (Lusser et al. 2012). Though it is important to define 
criteria and indicators for the assessment of socio-economic impacts, it is 
also necessary to define a common starting point and provide a framework 
for the discussion process of this broad and complex issue (Anita 2011). 
For example, COGEM has formulated nine themes and criteria which can 
serve as building blocks in an assessment of the contribution of GM crops 
towards more sustainable agriculture. Many socio-economic aspects which 
need to be accounted for in LMO cultivation are summarised in it. The 
closely related building blocks are as follows: benefit to society, economics 
and prosperity, health and welfare, local and general food supply, cultural 
heritage, freedom of choice, safety, biodiversity and environmental quality. 
For the operationalisation of these criteria, it is desirable that the indicators 
used to measure these criteria are objectively measurable and can be 
estimated in advance (COGEM Report 2009). 
In fact, there are differences which can be found in practice for instance 
while comparing National Sustainability Plans of the countries (NSDS) 
while adopting these criteria. These differences translate into indicators 
which vary widely across countries. Some NSDS specify relatively few 
(mostly environmental) indicators. Others have adopted large indicator 
systems (OECD 2006). A survey of NSDS of the EU Member States also 
revealed differences in the dimensions considered. Some Member States 
consider additional dimensions also; for instance, Slovakia, Poland, the 
93
Czech Republic, Estonia, Slovenia, and France have added an explicitly 
cultural dimension to the strategy emphasising local traditions, value 
systems, arts and the preservation of historical and cultural heritage as 
an integral part of sustainable development (Spok 2010).  But many of 
these are difficult to measure and the concept of sustainable development 
is like an umbrella word under which one can place any factor or socio-
cultural-economic dimension. Ivan Illich wrote about amoeba words whose 
meanings keep changing according to the users and contexts. The linkage 
between sustainable development, LMOs and socio-economic aspects is 
turning out to be an exercise in adding more to a wish list than an exercise 
in a realistic assessment. In our view, this approach by European countries 
is not suitable for developing countries or LDCs where food security and 
farm productivity are major issues. By adding more elements or criteria to 
socio-economic aspects no useful purpose will be served.  
But the alternative to the European approach is not neglecting SECs 
or using them as a cosmetic piece in the regulatory and decision making 
process. In our view, there is a strong case for an appropriate and integrated 
framework in SECs in decision making. The framework we propose will 
consist of two different and distinct levels of decision making on LMOs. 
The first level will be regulatory decision making based on scientific and 
technical aspects. In this the safety, efficacy aspects, including health 
and environmental impacts, will be considered as key parameters to 
take a decision. With respect to environmental impacts while impact on 
biodiversity will be considered that will be solely on natural biodiversity and 
will eschew linking culture and biodiversity or values and biodiversity in 
regulation and decision making. This level of decision making will consider 
safety, efficacy and effectiveness as three criteria to assess, prima facie, the 
technology per se and its utility. 
Safety, Efficacy and Effectiveness – The Three Issues in Assessment 
of Technology
Safety includes food safety, environmental safety and is assessed through 
risk assessment and by following globally accepted guidelines to assess 
safety (for example, WHO standards, CODEX guidelines) and accepted 
practices to evaluate the quality and sufficiency of experiments done in 
labs and field experiments. The accepted practices are available and are in 
public domain. Unless safety assessment is made no permission is granted 
to commercialise.
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Efficacy has direct socio-economic implications as it is tested by 
comparing the agronomic performance with the projected/estimated 
performance. Efficacy can be quantified and verified and it can be tested 
over a period of time also. For example, if it is projected that Bt toxin in 
BT plants will kill 70 per cent of the target insects this is measurable and 
verifiable in field trials and similar claims can be verified. There are benefits 
that may not be claimed or projected but may arise on account of efficacy. 
For example, while the primary efficacy can be tested in terms of percentage 
of target pests killed, increase in yields and reduction in use of pesticides 
are not the primary measures of the efficacy of (Bt) technology. The direct 
socio-economic implications of efficacy are to be taken into account. In 
other words, the more the efficacy is, more may be the socio-economic 
implications in terms of different parameters. 
Safety and efficacy are determined by technology and hence are 
technology dependent. Evaluating safety and efficacy is an assessment of 
technology per se and not technology as applied. Hence, any assessment 
of both these cannot be translated into direct socio-economic implications 
for decision making. These assessments may indicate the socio-economic 
implications.
Effectiveness: The effectiveness of a technology is tested under different 
conditions and in different contexts. Effectiveness is often influenced by 
factors that are outside technology and hence efficacy and effectiveness 
have to be understood as two categories. For example, Efficacy studies may 
indicate results which may not be repeated in commercial cultivation. For 
example, if a Bt variety recommended for cultivation in irrigated land is 
used in dry land agriculture then the outcomes are likely to be different 
from what studies on efficacy pointed out. Environmental factors, cost 
factors and other factors like handling/management of technology affect 
the effectiveness and as a result the variance in effectiveness is the result 
of many factors that have nothing to do with technology per se. But for 
assessing socio-economic impacts studies on effectiveness are necessary as 
they indicate the outcome of technology as applied in different conditions. 
But here too it is desirable to do ex-ante and post-ante studies and assess the 
performance in real world.
Regulation: For a regulator assessing the technology per se, assessing the 
two, technology dependent factors are critical because prima facie, whether 
the technology can be approved or not is the issue. Unless the technology 
meets the norms, the regulator can refuse permission to commercialise it. 
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But even after one regulator approves it, there can be other norms that have 
to be met for commercialisation or application on a wider scale.
For example, a Seed Regulator may stipulate that new seed varieties 
that show less than 10 per cent yield increase in coordinated field trials in 
different climatic zones will not be approved for cultivation as they do not 
meet the effectiveness criteria although they might have met the efficacy 
and safety criteria. 
Incorporating Socio-economic Aspects in Decision Making
The second level decision making will give importance to socio-economic 
aspects but socio-economic aspects will in general be limited to a maximum 
of six issues/parameters that are appropriate and relevant with respect to 
the LMO/GMO in question. From these six issues the most important three 
issues will be identified based on their relevance. Comprehensive studies on 
socio-economic aspects of them will be done and suitable methodologies 
will be developed. For example, economic impacts in terms of productivity, 
income for farmers, reduction in inputs and their costs are important in 
determining whether the LMO/GMO is a better one in terms of economic 
indicators. The social dimension is important but deciding on the social 
aspects or factors that need to be understood and studied cannot be decided 
a priori for all LMOs/GMOs. But how to choose the most appropriate social 
indicators or aspects is an important question. One way to approach this is 
to use methods like surveys, dialogues with stakeholders including those 
communities/classes that will be impacted upon by the proposed use of 
LMO/GMO to identify what issues/factors matter to them most in this issue. 
For example, in case of indigenous communities their perception that this 
LMO/GMO may violate their cultural norms may be important, perhaps 
more important economic impacts where as for other communities this 
may not be an issue. In such cases the decision making process should be 
sensitive to these perceptions and try to address them. 
While most of these socio-economic assessments/studies will be done 
in Pre-Production stage, there are socio-economic considerations that are 
important in other stages also as briefly described in Table 1. 
In the integrated framework we suggest that assessment of technology 
and assessment of socio-economic aspects should be done at distinct levels. 
The socio-economic aspects should be integrated in the framework not as 
an after thought or for the purpose of data collection but for the purpose 
of assessing the impacts of LMO/GMO including socio-economic aspects. 
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Table 1 Proposed Socio-economic Considerations for LMOs  
at various Stages
Pre-Production Production Marketing 
Post Production 
Monitoring 
•	 Testing of efficacy 
and environmental 
and health safety.
•	 Assessments 
are based on 
globally accepted 
methodologies, 
protocols and 
standards in testing 
and data analysis.
•	 Safety assessments 
need science 
based risk 
assessment based 
on quantifiable, 
verifiable and 
experimental 
evidence. 
•	 Testing of 
effectiveness of 
the technology. 
•	 Many factors 
influence 
effectiveness 
including 
technology 
independent 
factors. 
•	 Results of 
effectiveness tests 
may vary from 
results of efficacy 
tests.
•	 Tests of 
effectiveness 
can be directly 
relevant for socio-
economic impacts. 
· Traceability and 
labeling of LMOs.
•	 Products can be 
withdrawn if 
unforeseen adverse 
effects on human/ 
animal health or 
on environment 
are revealed.
· Gives correct 
information to the 
consumers. 
•	 Tests the long 
terms impacts. 
•	 Investigates the 
occurrence of 
any potential 
adverse effects of 
a LMO that were 
identified during 
the pre-production 
phase and assess 
their significance.
•	 Identify the 
occurrence 
and impact of 
unanticipated 
adverse effects of 
LMOs that were 
not predicted in 
pre-production 
assessments.
•	 Post production 
data is compared 
against the 
baseline data of 
the environment 
in which the 
LMO has been 
introduced.  
Source: Chaturvedi, Sachin, Srinivas, Krishna Ravi, Joseph, Reji K and Singh, Pallavi. 2012.
The assessment of  socio-economic aspects is necessary but not sufficient 
to take informed decisions. In some cases even when the economic impact 
is beneficial, the environmental impact on biodiversity may be a reason 
for not granting approval. In some cases it is necessary to ensure that there 
is no ‘contamination’ from GM crops to crops which enable a country to 
earn huge foreign exchange because of quality of produce and the distinct 
features of the produce (e.g. Basmati). In this case the trade dimension is 
too important to be ignored. The differentiation among Socio-economic 
Considerations as indicated in the Table 1 in different phases is necessary so 
that depending upon the effects, policy making can be done. Thus, in this 
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approach socio-economic considerations are taken into account depending 
upon their relevance for decision-making. 
Conclusion
Incorporating socio-economic aspects into decision-making is a challenge 
as there are many methodological issues to be resolved and there is no 
consensus on what constitutes socio-economic aspects. The European 
approach is comprehensive but not useful for developing countries as 
that approach does not method a methodology that is relevant in the 
developing nations’ contexts. Different countries have addressed this 
question in different ways. In this article, we have given the outline of one 
approach which in our view is more appropriate for developing nations 
and Least Developed Countries as this differentiates regulation from 
assessment of socio-economic aspects and at the same time ensures that 
socio-economic considerations are given due consideration in different 
stages of commercialisation.  
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In this incisive book, the historian of science and technology Jonathan 
Harwood meets with noteworthy success in his forthright attempt at a 
dialogue between the history of European agriculture and development 
studies. This book should be required reading for every student of the Green 
Revolution and contemporary debates regarding agricultural development.
Harwood’s latest publication contains an introduction followed by eight 
chapters. As the author usefully points out in the introductory chapter, his 
work is aimed at a variety of audiences, with some of the chapters relevant 
to agricultural historians (Chapters 1 through 5, which trace the rise and fall 
of peasant-friendly breeding in Europe between 1880 and 1945), and others 
(Chapters 6, 7 and 8, which record the extraordinary degree to which post-
1945 Green Revolutionaries appear to have dismissed the success or failure 
of earlier development programmes) appealing more to those academics 
and practitioners concerned with development of the global South. Those 
interested in questions of science and public policy are directed to focus 
upon Chapters 4 and 8 that have to do with the mantra that public-sector 
institutions should fix their attention on fundamental research, leaving 
applied work to the ‘more efficient’ private sector. Since it is difficult to 
do justice to the entire book in a short review, I will concentrate on those 
arguments and evidence presented by the author that would be of the 
greatest interest to the readers of this journal on agri-biotechnology and 
development.
In the preface, the author states that he has three objectives in mind: 
first, to contribute to the emerging literature on the history of plant 
breeding, which aims to connect breeding in absorbing ways to a range 
of general issues. Harwood remarks that the emerging body of work is 
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significant because it gives us a perspective to better understand and evaluate 
current controversies surrounding the genetic engineering of organisms 
and the patenting of life forms. To this end, in Chapter 4, he presents a 
history of the disputes between the state-funded public sector plant breeding 
stations and private sector companies engaged in that same work in south 
Germany during the phase 1902-1933. He gives evidence that public sector 
support for small firms is important for innovation across the sector as a 
whole, and he argues that large companies are interested in dominating 
the seed market by destroying competitors (small firms or the public sector 
institutions) in the name of ‘competition’ and the ‘free market.’
His second objective is to present a magnified and revised history of 
the Green Revolution. Conventionally, the Green Revolution is supposed 
to begin around 1945 and end in the 1970s. However, Harwood locates 
the beginnings of the Green Revolution in late nineteenth century Europe. 
He gives more attention to the later phases of the history of the Green 
Revolution, that is, from the 1970s to the present. As Harwood mentions, 
the gain from stretching out the Green Revolution to cover the period 
1880-present is that the patterned nature of its history becomes more 
evident. The author draws upon secondary sources to argue that the Green 
Revolution has gone through alternating phases in which its principal 
interest has shifted between boosting production and securing social equity. 
Thus, the chief concern of Green Revolutionaries during the first phase 
(1945-1970) was to boost production while that of the proponents of the 
second phase (1970s and 1980s) was to focus on social equity. Productivist 
concerns have become prominent during the third phase (1990 onwards), 
which is also the age of the ‘Gene Revolution’ or agri-biotechnology or the 
‘Second Green Revolution.’
The author’s third objective is to show how the history of Green 
Revolution might be of practical use in informing development policy. 
The idea is that institutions, including the development industry, have 
something to profit from reflecting upon their experience. Harwood claims 
that his analysis shows a surprising lack of interest by the development 
industry in its own past. He comments that the need to ‘look back’ before 
taking decisions regarding the future has become pressing since the 1980s 
through the ascendancy of neo-liberal political thought in many countries. 
Remarking on the task of the historian of agricultural development, he 
writes on page xv: “That markets should routinely be given preference to 
state action, however—not least in development policy—seems to me to 
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be grounded far more in ideology than in the analysis of past action and 
its consequences. There is a great deal at stake here, and it is important 
that those of us who know something about the past should speak up.”
Apprehensive about being pigeon-holed as a technology-pessimist, 
Harwood makes it clear in his prefatory remarks that he is not a Luddite 
(defined by him as “critics of quasi-romantic inclination who attack 
the technology central to industrial agriculture for poisoning our food, 
contaminating the environment, and fatally undermining the family 
farm. For them, the solution is seen to lie, not in improved technology, 
but in indigenous knowledge and ‘traditional’ cultivation practices.”). 
Neither is he a ‘high modernist’ (cf. Scott 1998), those who advocate the 
‘modern’ agricultural science underpinning the Green Revolution as the 
only effective way to prevent the occurrence of hunger and poverty in 
developing countries. Terming both Luddite and ‘high modernist’ visions 
as exclusive, Harwood argues against such exclusivism, and says that the 
“most promising solutions to rural hunger and poverty [whether in Europe 
around 1900 or in the contemporary global South]…are instead those 
that are synthetic; they combine the methods of science and technology 
with the best that indigenous knowledge and practice have to offer (page 
xvi).” However, Harwood does not provide any examples or case-studies 
of appropriate technology in the global South that have successfully met 
the challenges of both low yields and social inequity. If such examples 
do not exist in history, then the task of creating synergy between ‘high 
modernist’ (whether they belong to the private sector or the public sector) 
and ‘Luddite’ visions in the age of biotechnology becomes all the more 
difficult. Another problem is that Harwood does not make it clear how 
his use of the term ‘appropriate technology’ differs from the common 
usage of that term (for example, by Ernst Schumacher in his 1973 book 
Small is Beautiful) in the literature on development studies. Does the term 
‘appropriate technology’ envisage any role for large private-sector firms 
in the seed markets, or does it see a future only for public sector breeding 
stations which co-exist with many small private-sector firms? Does the 
term ‘appropriate technology’ resonate with the prohibitively costly 
transgenic technology? Is biotechnology-based agriculture amenable to 
local (by which I mean community-based) control? These are just a few 
questions that emerge upon reading about Harwood’s championing of 
‘appropriate technology’ as a way to effectively deal with both Luddism 
and high modernism.
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I will briefly address the central goals of each chapter. The first 
five chapters of the book have to do with the appearance of the south 
German plant-breeding stations as well as their work, impact and decline. 
Chapter 1 deals with the political and economic context within which 
nineteenth century German agricultural authorities decided to establish 
peasant-oriented institutions for extension and research. In Chapter 2, 
the center shifts to south Germany during the 1890s where a conjuncture 
of movements and concerns prompted agricultural ministers to see state-
funded plant breeding as both economically and politically desirable. In 
the third chapter, the author narrates the early history of the south German 
stations up to 1914, noting their organisation, growth and activity in 
varietal testing, breeding and extension work. Chapter 4 deals with the 
interwar period, by which time the state-funded plant breeding stations 
had begun to make a definite economic impact but also became immersed 
in disputes. The chief focus of Chapter 5 is the period of National Socialism 
when, despite the regime’s oft-announced support for peasant agriculture, 
the stations came under considerable pressure to abandon their peasant-
friendly mission in order not to compete with private-sector breeding. 
The last three chapters trace the history of the Green Revolution from 
the 1940s into the contemporary phase. In Chapter 6, after introducing 
the Green Revolution and its critics, Harwood examines the efforts by 
development experts from the 1970s to establish why the revolution had 
largely failed to benefit smallholders. Their diagnoses are then ‘tested’ 
against a particular case: the early history of the Green Revolution 
in Mexico. In the next chapter, he asks to what extent this period of 
criticism and reflection gave rise to peasant-friendly reforms of the Green 
Revolution, beginning with new approaches from the 1970s (agroecology, 
farming systems research, participatory plant breeding). It concludes 
with an assessment of the status of peasant-oriented approaches today 
and an examination of the recent claims that biotechnology offers the 
most promising foundation for a ‘second Green revolution.’ In Chapter 8, 
Harwood places the history of the Green Revolution in a wider political-
economic context, summarised the argument that state-funded agricultural 
research offers a viable development strategy for peasant farming, but 
conceded that such a strategy is unlikely to make much headway so long 
as the development industry remains structured as it is.
Harwood comments that though some claims for biotechnology’s 
peasant-friendly potential are entirely plausible (and gives examples of such 
innovations), the key question is: what is the likelihood that this potential 
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payoff will be realised? The author explains how the public sector has been 
deliberately rundown in all countries since the 1980s and there are no 
signs that this situation is changing. The private sector is now dominant in 
biotechnology. Regarding public-private partnerships to solve the funding 
problem, Harwood warns that the terms of such collaboration will have to 
be negotiated very carefully. For example, NGOs have already expressed 
concern that some of the CGIAR centers’ existing partnerships threaten 
to divert the center’s work away from the needs of small farmers. So, what 
are the prospects for biotechnology-based breeding helping resource-poor 
farmers in future? Harwood argues that the concentration of biotechnology 
in the private sector, the weakness of public-sector agricultural research, 
and the very few public-private partnerships so far all suggest that these 
prospects are poor. Indeed, some argue that the diffusion of biotechnology 
in the developing world is likely to widen the gap between commercial and 
subsistence farmers, and the evidence from Latin America seems to bear 
this out. Faced with such evidence, many advocates of biotechnology insist 
that the technology will be capable of serving smallholders once a series 
of ‘obstacles’ have been removed. It is essential, they argue, that (a) the 
private sector be encouraged to invest in this area (e.g. through protection 
of intellectual property rights, reasonable biosafety regulations, and state-
funded incentives which encourage pro-poor research) and (b) governments 
in the South fund public-sector biotechnology research and provide input 
subsidies to small farmers. This optimistic view, however, turns a blind eye 
to the serious limitations of both private and public sectors. By arguing 
that governments in the global South merely need to get their policies 
on biotechnology right, advocates have simply ignored the fundamental 
political fact that over the last thirty years or so, the public sector has been 
deliberately weakened in all countries except for China. Harwood provides 
some excellent evidence of what Chinese public sector has done for peasant 
farmers in that country, but it would have been more useful if he had 
devoted a chapter to show how the post-1949 Chinese state’s attempts to 
meet the needs of peasant farmers converges with or diverges from the past 
peasant-friendly Green Revolutions in Europe and Japan.
Harwood poses the question: if the evidence is so unconvincing that 
the developed world’s biotechnology will alleviate rural poverty, why do 
the proponents of biotechnology never seem to tire of advancing this 
claim? The author gives reasons as to why three social groups (scientists, 
biotechnology industry, and major donor agencies) have jumped on 
the biotechnology bandwagon. Scientists are lured by the promise of 
104     Asian Biotechnology and Development Review
an easy technological fix for all kinds of socio-economic problems. The 
biotechnology industry focused on the poverty-alleviation claim during 
the 1980s in order to make a business case to investors, and since 2000 in 
its zeal to combat the European people’s intransigence on transgenic crops. 
Regarding the donor agencies, Harwood opines that one might have hoped 
that these organisations’ familiarity with the complexities of development 
might have vaccinated them against unduly simple solutions. If ‘miracle 
seeds’ could not deliver the poverty alleviation that was promised in the 
first generation of the Green Revolution, why should one expect a ‘miracle 
technology’ to do so in the third generation? The answer here, Harwood 
thinks, requires us to reflect upon the very nature of the development 
industry, a task he defers to the last chapter.
In the last chapter, the author looks upon the material he has 
presented in the last eight chapters from three different perspectives. He 
draws conclusions which are respectively analytical, hopeful and bleak. 
The first of these is an attempt to place the material the author has 
surveyed within a wider theoretical framework. The second is a normative 
conclusion in which he outlines what he believes the implications of his 
historical analysis are for development policy. The third perspective is a 
rather pessimistic series of reflections upon the nature of the development 
industry today whose implications is that, given the way in which it 
currently operates, ‘the lessons of history’ are unlikely to make much 
impact upon development strategy.
Harwood expresses the view that International Agricultural Research 
Centres (IARCs) and National Agricultural Research System (NARS) can 
be potentially of crucial importance for smallholders provided they are 
adequately funded by different entities. He states that if rich countries 
were to divert just two per cent of their agricultural research budgets to 
the developing world’s NARS, the latter’s budgets would more than double. 
Undoubtedly, there is plenty of money available which could be used to 
strengthen the global South’s public-sector R&D. He comments that if rich 
countries choose not to spend it in this way, it is a political decision. Later, 
in this chapter, he agrees with Gilbert Rist (2008)’s stringent critique of 
development as an “ideological commitment and a vehicle for achieving 
a range of often political aims, not an empirically based learning process 
that seeks poverty alleviation.” If we have indeed reached an impasse when 
it comes to agricultural development, then why did the author bother to 
argue the case that peasant-friendly development can be fostered by state 
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research institutions? Harwood gives some evidence to make his point that 
the development industry is not monolithic, and this very existence of 
pluralism makes him hope as a historian that some development agencies, 
theorists and practitioners will reflect upon the past while trying to devise 
more effective strategies for the future. One hopes that this important 
contribution by Harwood to the literature on agricultural development 
combined with his earnest plea for the revitalisation of state-funded research 
institutions will reach the ears of biotechnologists and policymakers in 
both rich and poor countries. 
--Devparna Roy
Visiting Fellow, 
Polson Institute for Global Development, 
Department of Development Sociology, 
Cornell University
E-mail: dr53@cornell.edu
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Regulation of technology at a global level is a challenging task, particularly 
for technologies like biotechnology that have wider applications in many 
fields with rapid advances in the technology. If at all anything easy answers 
elude the question of regulating nanotechnology and synthetic biology, 
whether it is at national level or regional level or global level1. On the 
other hand, regulatory divergences are more a norm across nations than 
an exception in many fields including regulating drug safety.2 Thus, while 
there may be a need for global regulation of some technologies given 
their impact and wider use, it has not been an easy task to evolve a global 
regime or a Treaty or Convention for this purpose. Part of the problem lies 
in differences in approaches to risk assessment and also the variance in 
public policy that sets the limits for application of a technology.3
In the book under review Catherine Rhodes embarks on a challenging 
task – arguing for international regulation of biotechnology by examining 
the current regulatory frameworks relevant to biotechnology at the 
global level. Although the title mentions Governance the book calls for 
international regulation which is synonymous with Governance. Topics 
like this can be analysed from different disciplinary perspectives and the 
author has chosen International Law as the discipline to ground her analysis 
and to make a case for international regulation. 
Chapters 2, 3, and 4 discuss the biotechnology revolution, its impacts 
and potentials, and the need for regulation.  In the next two chapters, 
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the author examines the model for coherent international regulation 
and identifies thirty seven international regulations that are relevant in 
regulation of biotechnology. In the next five chapters, the author provides 
an extensive analysis of the regulations and compares them with the model 
regulation that she considers as desirable and assesses the regulations 
in terms of sixteen characteristics. Finally, based on these chapters she 
argues for regulation at international level for effective governance of 
biotechnology revolution so that while its benefits are maximised, the 
negative impacts are eliminated or minimised. In this regard, she examines 
the coherence or its lack among these regulations and suggests how more 
and better coherence can be ensured. Thus, the conclusion is a call for 
international regulation of biotechnology which will be based on some 
core principles.
The important chapters from the point of view of the reviewer are from 
five to eleven in which she analyses the current regulations and points 
out the problems with them so as to build an argument for international 
regulation. However, I find it problematic that her set of regulations 
includes agreements like TRIPS or guidelines for biosafety and international 
agreements whose central concern or objective is not regulation of 
biotechnology. Thus, if one applies a different criteria or definition of 
regulation, then the number of regulations will be reduced considerably 
as only agreements, treaties and Declarations, whose core objectives are 
related to or include biotechnology regulation, need to be considered. 
Moreover in case of declarations she has cited they are more concerned 
with what is permissible and what are desirable and not desirable than 
regulating biotechnology per se. For example, the Declaration on Cloning 
indicates what is permissible and what is not but regulation of a technology 
is more than that, although the boundaries of application of technology 
are set by such declarations and often by national level policies that are 
consistent with such declarations. Thus, if one goes by a stricter definition 
of regulation then not only the number of regulations is reduced but also 
a portion of the subsequent analysis by the author becomes redundant. 
This I think is a major issue with the book because not all may agree with 
her categorisation of relevant regulations. Some of the regulatory hurdles 
at the international level stem from lack of coherence among regulations 
and also from universally accepted norms of risk governance. The interface 
between trade regulation and environmental regulation is another issue 
that is very relevant to the questions raised by the author. But these do 
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not get the attention they deserve in this book as the author deals with as 
many as thirty seven regulations and her analysis summarised in tables is 
revealing and important. 
The author takes the Geneva Conventions and Protocols as model 
as they provide coherent set of international regulations and also points 
out that the same is true of Dangerous Goods Regulation and UN Drugs 
Convention. But these are not dealing with a fast advancing technology 
and hence while they may be models of international regulation, they 
cannot be considered as models for international technology regulation. 
Hence the question that should have been pursued is what is an ideal or 
preferable model for technology regulation at the international level, that 
also has key features of accepted models of international regulation from 
an international law perspective. The models she has chosen are not totally 
irrelevant as she is analysing them in terms of key principles and how 
they are coherent with each other. Thus the point that coherence among 
regulations is important and in that aspect the examples are very apt. 
Based on the model and her detailed analysis of each of these regulations 
in terms of structure, institutional mechanism she critically examines their 
shortcomings and how these regulations lack coherence with each other 
and points out the overlap among them. This is the core of her argument 
and this is well developed, and the criteria she has used are very useful in 
unraveling the coherence or its lack and the scope of each of the regulations. 
According to the author, “The biotechnology regulations fail to match the 
four characteristics of the coherent regulatory model covered in this chapter. 
There is some self-referencing among regulations within and between issue 
areas, but not for the set as a whole and not always with relevance to control 
of biotechnology” (pp.144). Similarly, she identifies 15 institutions that are 
relevant for biotechnology regulation.
Using 16 characteristics and 15 functions as criteria she evaluates 
the international regulations applicable to biotechnology and points out 
that they lack coherence and provides examples for this. But some of the 
examples are not convincing, partially because, as pointed out earlier, some 
of the regulations are not relevant to regulating biotechnology at the global 
level (e.g. TRIPS Agreement, Bonn Guidelines). Hence, in my view, her 
argument on existence of different dispute settlement mechanisms (pp.166-
167) is not valid.  While in some instances, there are issues like which Treaty 
or Agreement is applicable, this aspect has not got the attention it deserves 
by the author. For example, the question of using Socio-Economic Aspects 
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under Article 26 of Cartagena Protocol to block import of Living Modified 
Organisms (LMOs) is cited by the author in the context of whether this 
is applicable or whether WTO rules apply. But the analysis is too brief 
and it does not even scratch the surface. A deeper analysis would have 
revealed that while this is an important question, part of the answer lies 
in Article 26 itself which recognises obligations under other international 
treaties. Thus while there is scope for dispute under WTO in such a case, 
the issue would be different and that would be whether such an action, 
that is blocking import of LMOs, is consistent with WTO rules or not. 
In fact, the author could have used this example and cases before WTO, 
to point out the major problems in current regulation of biotechnology. 
Having exhaustively analysed these regulations she builds up a case of 
international regulation of biotechnology and makes suggestions that 
would enhance coherence among international regulations. 
The author has tried to address an important problem and has come 
up with some suggestions. But on account of the problematic nature 
of the set of regulations in terms of their applicability as regulations of 
biotechnology, subsequent analysis suffers from many flaws, some of 
which have been pointed out in the previous paragraphs. The author 
could have explored linkages and interfaces in trade and environment 
disputes and could have used the extensive literature on WTO cases to 
buttress her case for coherent international regulation of biotechnology. 
However, whether such a global regulation is feasible, or for that matter 
desirable, is a different issue. One way to address this issue is to examine 
whether in some applications of biotechnology, international regulation 
is necessary to meet some objectives and if so what are those applications 
and how to develop and deploy global regulation for such applications. 
Given the broad and expanding nature of biotechnological applications 
and uses, it is better to categorise in terms of applications in a field (e.g. 
health biotechnology) and examine the case for international regulation, 
and ensure that the interface and linkage between set of regulations 
in this area/application and other important agreements like WTO are 
well understood and scope for coherence is increased, than to argue for 
a global regulation for whole of biotechnology. It is true that although 
there are issues with current regulation of biotechnology under different 
agreements, conventions and treaties, the situation is not so alarming to 
call for a global regulation as envisaged by the author.
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As a book that addresses an important issue in regulating biotechnology, 
this will be of interest to anyone interested in global regulation of 
technology and international law and technology.  It raises many important 
questions, most of which elude easy answers. 
--K. Ravi Srinivas
Associate Fellow, RIS and 
Managing Editor, ABDR
Email: ravisrinivas@ris.org.in
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